Optimization of antipsoriatic treatments with special reference to monitoring of methotrexate-induced liver toxicity. by Berends, M.A.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/71086
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Optimization of
antipsoriatic treatments with 
special reference to monitoring of 
Methotrexate-induced liver toxicity
M.A.M.Berends
Berends, M.A.M.
ISBN:
Print:
Design and Layout:
Optimization of antipsoriatic treatments with 
special reference to monitoring of
methotrexate-induced liver toxicity.
Thesis Radboud University Nijmegen Medical 
Center, Nijmegen, The Netherlands, 
with summary in Dutch; 116 p. ©2008
ISBN-13: 978-90-9022727-6
Printpartners Ipskamp, Enschede
M.K.P. Poll & M.A.M. Berends
No part of this book may be reproduced in any form without written permis-
sion of the author. All published papers are reprinted with permission and 
with credit to their resource.
ter verkrijging van de graad van doctor aan de
Radboud Universiteit Nijmegen op gezag van de 
Rector Magniﬁcus, prof. mr. S.C.J.J. Kortmann,
volgens besluit van het College van Decanen
in het openbaar te verdedigen op
vrijdag 28 maart 2008 om 10.30 uur precies
Een wetenschappelijke proeve op het gebied van de
Medische Wetenschappen
DOOR
Maartje Adriana Marike Berends
geboren op 16 april 1977 te Boko, Benin, Afrika
Optimization of
antipsoriatic treatments with 
special reference to monitoring of 
Methotrexate-induced liver toxicity
PROEFSCHRIFT
Promotores:
Copromotor: 
Manuscriptcommissie:
Paranymfen:
Prof. dr. dr. P.C.M. van de Kerkhof
Prof. dr. J.P.H. Drenth
Dr. E.M.G.J. de Jong
Prof. dr. P.L.C.M. van Riel
Prof. dr. J.H.J.M. van Krieken
Prof. dr. P. Smits
Drs. L. Bruijstens
Drs. J.E. Körver
“Take each man’s censure, but reserve thy judgment.”
William Shakespeare
Voor Erik, mijn ouders, Saskia en Dick

ABBREVIATIONS
Desoxy-ribonucleic-acid
European Medicines Agency
Glucocorticoid Response Element
Intercellular Adhesion Molecule-1 (CD54)
Leucocyte function-associated antigen-1 (=CD11a/CD18)
Leucocyte function-associated antigen-3 (=CD58)
Methotrexate
Nederlands Huisartsen Genootschap
Psoriasis Area and Severity Index
Percentage of patients achieving 50% or more reduction 
in PASI
Percentage of patients achieving 75% or more reduction 
in PASI
Aminoterminal propeptide of procollagen type III
Psoralen and Ultra Violet A
Retinoid Acid Receptor
T helper 1
T helper 2
Tumor Necrosis Factor
Tumor Necrosis Factor Receptor
Ultra Violet B
Vitamin D Receptor
Vitamin D Receptor Element
DNA:
EMEA:
GRE:
ICAM-1:
LFA-1:
LFA-3:
MTX:
NHG:
PASI:
PASI-50:
PASI-75:
PIIINP:
PUVA:
RAR:
Th1:
Th2:
TNF:
TNFR:
UVB:
VDR:
VDRE:
11
13
15
17
17
18
20
21
24
24
25
25
26
28
35
37
45
47
55
63
Chapter 1
 General Introduction
1.1 Focus of this thesis
1.2 Epidemiology and clinical presentation of psoriasis
1.3 Aetiology and pathogenesis of psoriasis
1.4 Available treatments of psoriasis
  1.4.1    Topical treatments
  1.4.2    Photo(chemo)therapy and classical systemic therapy
  1.4.3    Biological therapies
1.5 Limitations of the available treatments of psoriasis. 
 in speciﬁc:
  1.5.1    Topical treatments
  1.5.2    Photo(chemo)therapy
  1.5.3    Systemic treatments
  1.5.4    Biological therapies
1.6 Aims of this thesis
Chapter 2
 An improvement in the topical treatment  
 of psoriasis
The effect of the combination of calcipotriol and betamethasone
dipropionate versus both monotherapies on epidermal prolif-
eration, keratinisation and T-cell subsets in chronic plaque 
psoriasis.
Chapter 3
 How to improve monitoring of liver toxicity  
 in patients treated with Methotrexate
3.1 Dermatologists’ adherence to the guideline of the Dutch
 Society of Dermatology and Venereology with respect
 to the treatment with Methotrexate for severe chronic
 plaque psoriasis: Results from a Dutch survey
3.2 Liver injury in long-term methotrexate treatment in
 psoriasis is relatively infrequent.
3.3 Biochemical and biophysical assessment of MTX-
 induced liver ﬁbrosis in psoriasis patients: Fibrotest
 predicts the presence and Fibroscan predicts the
 absence of signiﬁcant liver ﬁbrosis
TABLE OF CONTENTS
3.4 The reliability of the Roenigk classiﬁcation for liver
 damage after methotrexate for psoriasis. A clinico-
 pathologic study of 160 liver biopsies.
Chapter 4
 Management, efﬁcacy and safety of
 Biologicals in routine use
 Etanercept and efalizumab treatment for high-need
 psoriasis. Effects and side effects in a prospective
 cohort study in outpatient clinical practice.
Chapter 5
 General Discussion
5.1 General Focus
5.2 Recommendations for adaptation of available
 guidelines
5.3 Future Directions
Chapter 6
 Summary
6.1 Summary
6.2 Samenvatting
Curriculum vitae
List of publications
Dankwoord
71
77
79
89
91
96
97
105
107
109
112
113
115

Chapter
1
General Introduction

Chapter 1 - General Introduction
13
1.1 Focus of this thesis
Psoriasis is a chronic and incurable disease with an average onset 
during the second decade of life. This means that many patients are 
challenged to manage their disease for decades.
 In the Netherlands two guidelines are available for the man-
agement of patients with psoriasis: the ‘NHG standaard’, which focus-
es on topical treatments and which has been created by the general 
practitioners and the guideline ‘photo(chemo)therapy and systemic 
therapy’ which is the guideline of the Dutch Society of Dermatology 
and Venereology1-3. 
 Based on these guidelines but also based on the informa-
tion available in international reviews4,5 it is evident that a ‘step-
wise approach’, starting with topical therapy (1), followed by 
photo(chemo)therapy and classical systemic therapies (2), followed by 
biologics (3) is the ‘life of therapies’. The risk of toxicity increases with 
each sequential treatment in the stepwise approach. Various treat-
ment approaches, like rotation, combination, sequential and intermit-
tent therapy are used to reduce the risk of toxicity.
 The focus of the present thesis was to optimize the treatment 
of psoriasis, reconciling this treatment paradigm and to carry out a 
study in each of these 3 phases of intervention.
      Step1: In order to reduce the number of patients exposed to the 
potential side effects of systemic treatments and biologics, improve-
ment of efﬁcacy safety ratio of topical treatments with excellent safety
proﬁle is important. We have focussed on the combination of the vi-
tamin D3 analogue calcipotriol and the corticosteroid betamethasone 
dipropionate as an improvement in the topical treatment of psoriasis. 
A study was performed to ﬁnd out the effect of the combination and
of both monotherapies on psoriasis relevant T cells, in order to under-
stand the rationale of this successful combination (chapter 2).
      Step 2: Of the treatments photo(chemo)therapy and classical 
systemic treatments, methotrexate is a major treatment, which per-
mits long-term safe control with an impressive efﬁcacy. Of concern is
liver toxicity. Monitoring this hepatotoxicity is dealt with in the Guide-
line of the Dutch Society for Dermatology and Venereology. Howev-
er, amongst dermatologists, rheumatologists and gastroenterologists 
there is a major discussion whether monitoring of the liver with regu-
lar liver biopsies is needed. Chapter 3 addresses this question.
      Step 3: Despite optimization of topical and classical systemic 
treatments and various treatment approaches, the available topical, 
photo(chemo) therapy and classical systemic therapies may not pro-
vide adequate continuous long-term disease control in all patients. In 
such cases, the biologicals may be able to provide a more consistent 
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control of symptoms with a good safety proﬁle. Biologicals are indicat-
ed for patients with severe psoriasis who have failed all classical treat-
ments. Early 2005 the biologicals etanercept and efalizumab became 
available for routine treatment of a high-need psoriasis population. In 
chapter 4 the results of both biologicals in a new unit for routine care 
of these high need patients are described.
In chapter 5 the observations in chapters 2-4 will be integrated and 
recommendations for adaptations of the existing guidelines will be 
presented and perspectives for future development will be provided.
 
Deﬁnition
Psoriasis is a chronic recurring non-infectious, inﬂammatory disease
that can affect skin, nails and/or joints.
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1.2 Epidemiology and clinical presentation
 of psoriasis
Psoriasis is a common disease, affecting 1,5-3% of the world’s popu-
lation. There are racial variations with a high prevalence in western 
populations while the disease has not been observed in Native Ameri-
cans, Eskimo’s and Saami. Men and women are equally affected. The 
disease can occur at any age although two peak incidences have been 
reported: a peak between 16 and 22 years and a later one at 57-60 
years4,6-9.
 There are different disease variants of psoriasis with different 
cutaneous manifestations: combinations of these different forms are 
possible. The most common type is psoriasis vulgaris (chronic plaque 
psoriasis) which accounts for approximately 90% of all cases4-6,9.
 
Chronic plaque psoriasis is characterized by, often symmetrically dis-
tributed, sharply demarcated erythematosquamous plaques of vary-
ing size with predilection sites on the dorsal sites of the elbows, knees 
and on the scalp and sacral region. The scales of these lesions are 
typically silvery white and scratching these looks like scratching on a 
wax candle (“signe de la tache de bougie”). The course is chronic with 
exacerbations and remissions4,5. (ﬁgure 1)
Figure 1: Clinical presentation of psoriasis vulgaris with sharply de-
marcated erythematosquamous plaques (A) and guttate psoriasis with 
droplike erythematosquamous plaques on the skin (B).
A B
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 In guttate psoriasis (psoriasis gutatta) many erythematous and 
scaly droplet-like lesions are scattered diffusely over the body. It de-
velops particularly after streptococcal infections and often clears in a 
few weeks to months4,5. Sterile pustules and deep erythematous areas 
characterize pustular psoriasis. (ﬁgure 2) The pustules can be local-
ized (pustulosis palmoplantaris) or generalized4,5.
 Flexural psoriasis (psoriasis inversa) appears as non-scaly in-
ﬂamed patches in the skin folds, particularly in the axillae, groins,
submammary and peri-anal region and retro-auricular folds4,5.
 In erythrodermic psoriasis all or almost the entire cutane-
ous surface is involved and patients may become ill and febrile 
and develop hypothermia, dehydration and protein loss requiring 
hospitalization4,5.
 Extracutaneous manifestations of psoriasis are nail psoriasis 
(psoriasis unguium) and psoriatic arthritis. Nail involvement is present 
in 25-50% of all types of psoriasis and more frequently with psoriatic 
arthropathy. The most common changes seen in the nails are pitting, 
discolouration (oil drop phenomenon), subungual hyperkeratosis and 
onycholysis4,5. (ﬁgure 3) Psoriatic arthritis occurs in about 5-10% of 
the patients although this percentage is discussed: up to 39% has 
been suggested in the recent questionnaire by Europso4,5,10.
The studies in this thesis have been concentrating on chronic plaque 
psoriasis.
Figure 2:
Clinical picture of a gen-
eralized form of pustular 
psoriasis with deep-red 
erythematous areas and 
pustules.
Figure 3:
Clinical picture of a psoriatic 
involvement of the nail with 
typical pitting of the nail plate.
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1.3 Aetiology and pathogenesis of psoriasis
Psoriasis seems to be a multifactorial disease caused by the interac-
tion between genes and environmental triggering factors4,5.
 Several gene loci have been linked to psoriasis. It has been 
hypothesized that polymorphisms, both in genes involved in immune 
function and in genes involved in keratinocyte biology be responsible 
for psoriasis5,11. 
 Triggering factors may play a role in the initiation of the dis-
ease process and exacerbation of pre-existing disease. Triggering 
factors that have been reported are trauma (Koebner phenomenon), 
infections, drugs (β-blockers, lithium, antimalarials), endocrine fac-
tors (pregnancy), psychogenic stress, increased alcohol consumption, 
obesity, smoking and HIV4,5. 
 Histologically the disease is characterized by epidermal hyper-
proliferation with loss of differentiation, dilatation and proliferation of 
dermal blood vessels and accumulation of inﬂammatory cells (particu-
larly neutrophils and T lymphocytes)5. (ﬁgure 4)
1.4 Available treatments for psoriasis
Psoriasis is still an incurable disease, relapsing after cessation of any 
therapy. Treatment should be individualized and the decision to em-
ploy a particular treatment should depend on age, personality, profes-
sion, general health, intelligence and resources, quality of life, type, 
extent, duration and natural history of psoriasis. 
 Medications with the least potential toxicity are preferred and 
medications with signiﬁcant toxicity are preferentially restricted to
those patients with a physically, socially, economically or emotionally 
disabling and therapy resistant psoriasis. Outpatient topical therapy 
Figure 4: Histology of normal (A) and involved psoriatic skin (B)
A B
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should be the ﬁrst step in case of a stable psoriasis, causing as little as
possible disturbance in a patient’s routine. If topical treatment fails, 
the next step should be photo(chemo)therapy (UVB, PUVA). The third 
step involves treatment with one of the classic systemics: methotrex-
ate, cyclosporin, retinoids, fumaric acids. If all treatments have failed, 
the last step is treatment with the so called biologics1-3,5.
For more extensive reviews on antipsoriatic treatments the reader is 
referred to the literature.
 
1.4.1 Topical treatments
This section describes the current topical treatments for chronic 
plaque psoriasis: Emollients and keratolytics, Coal tar, Dithranol, 
Corticosteroids, Vitamin D3 derivatives, Calcipotriol/betamethasone 
dipropionate, Calcineurin inhibitors and Topical retinoids. 
Emollients and keratolytics
Emollients contain no pharmaceutically active components and are 
used to hydrate and soften dry skin. They can be used both in lesional 
and unaffected psoriatic skin. Keratolytics are prescribed to reduce 
the thick scale of psoriatic plaques to enhance the penetration of topi-
cal medications and phototherapy12.
Coal tar
Coal tar has been used in topical therapy for more than a century. It 
has anti-inﬂammatory, and also antimitotic effects, modulating the
itch and clinical severity of the psoriatic lesions. It can also be used in 
conjunction with UV therapy4,5.
Dithranol (anthralin)
Dithranol induces a cascade of free radicals in the skin, which reduces 
proliferation and inﬂammation. Patients can be treated with twenty-
four-hours application, which is highly effective but time consuming, 
or short-contact application, being both easier and more convenient 
for the patient. Because of habituation in case of repeated application, 
the concentration of dithranol should be cautiously increased with a 
maximum of 3 times a week, starting with 0,05 or 0,1%4,5,13,14.
Corticosteroids
Corticosteroids have been used for decades in mild to moderate pso-
riasis. On the face and neck, ﬂexures and genitalia mild corticoster-
oids are the ﬁrst-line therapy because other topical treatments can
induce irritation and potent corticosteroids induce atrophy at these 
sites. Corticosteroids can be given as monotherapy or in combination 
with other topical therapies5,15-18.
 Corticosteroids bind to an intra-cellular glucocorticoid-recep-
tor. This complex binds to a nuclear glucocorticoid response element 
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(GRE) resulting in anti-inﬂammatory, immunosuppressive and anti-
mitotic effects of these drugs19. Corticosteroids are manufactured in 
various vehicles (ointments, creams, lotions, foams and gels) with dif-
ferent efﬁcacy, ointments being most effective20. 
 To organize the available corticosteroids they have been classi-
ﬁed in class I to IV, class I being low potent, class II being potent and
class III and IV being super potent corticosteroids20. 
Vitamin D3 derivatives
Vitamin D3 derivatives are the ﬁrst-line treatment, as monotherapy
or in combination, in mild to moderate psoriasis. Because of their 
lipophilic character Vitamin D3 derivatives pass the cell membranes 
easily and ﬁnally bind to nuclear Vitamin D Receptors (VDR). This
complex binds to speciﬁc DNA sequences (Vitamin D response el-
ements (VDRE)) in the promoter region of certain vitamin D target 
genes that are involved in epidermal proliferation, inﬂammation and
keratinisation4,5,21-27. 
 At the moment there are three synthetic vitamin D3 deriva-
tives available for topical treatment of psoriasis in Europe: calcitriol 
(Silkis®), calcipotriol (Daivonex®) and tacalcitol (Curatoderm®). These 
topical agents are manufactured as ointment, cream or lotion20.
Calcineurin inhibitors
Calcineurin inhibitors block calcineurin, an important enzyme in-
volved in the calcium dependant signal transduction in T-cells, there-
by inhibiting the transcription and synthesis of various cytokines28. 
There are two different preparations: Tacrolimus ointment 0,03% or 
0,1% (Protopic®) and Pimecrolimus cream 1% (Elidel®)20. Calcineurin 
inhibitors are only an effective treatment for intertriginious and facial 
forms of psoriasis29,30.
Topical retinoid: Tazarotene
Tazarotene is a synthetic acetylenic retinoid (0,05% or 0,1%) and avail-
able as gel and cream. It has been shown to have anti-proliferative and 
anti-inﬂammatory activities and as such has a modest antipsoriatic
effect31. It has not been registered in the Netherlands.
Combination treatments
It is always of great importance to optimize the available treatments by 
improving efﬁcacy and reducing side effects. One way to accomplish
this might be by combining existing treatments. To increase efﬁcacy
and reduce side effects, combination treatment is advised for most of 
the patients. Coal tar and dithranol can be combined with any anti-
psoriatic treatment. However, there are few evidence-based studies.
 Tazarotene combined with topical steroids and UVB as been 
proven to be more effective and safe as compared to mono therapies. 
The ﬁxed combination of calcipotriol/betamethasone dipropionate
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(Dovobet®) has been proven to be more effective than twice-daily cal-
cipotriol or bethamethasone diproprionate mono therapy15,17,32-35. This 
two-compound product contains calcipotriol 50µg/g and betametha-
sone dipropionate 0,5mg/g20.
1.4.2 Photo(chemo)therapy and classical systemic therapy
Photo(chemo)therapy
If topical treatment is ineffective or in case of moderate to severe pso-
riasis with a large affected body area the next step is often photother-
apy. Available forms are broadband UVB (290-320nm), narrowband 
UVB (311 +/- 2nm) and PUVA photochemotherapy. UV irradiation 
is thought to exert immunosuppressant effects, and the induction of 
DNA damage and apoptosis in hyperproliferative keratinocytes4.
 Nowadays, narrowband UVB is the most optimal irradiation 
available with three times weekly appearing the optimum regimen for 
efﬁcacy. It has been found to be superior to conventional broadband
UVB in psoriasis, producing longer remissions with lesser side effects. 
In addition, narrowband UVB is more convenient and also probably 
less carcinogenic than PUVA therapy, although the effectiveness ap-
pears to be similar to each other. An interesting development is home 
narrowband UVB treatment. PUVA irradiation consists of UVA plus 
topical or systemic psoralens. PUVA is given 2-4 times weekly4,36,37. 
 Because long-term treatment with PUVA has serious carcino-
genic hazards, PUVA should only be considered as a primary treat-
ment in elderly patients in whom psoriasis covers at least 20% of the 
body surface, and who cannot be controlled by conventional topical 
therapy. In younger patients or in patients with less widespread pso-
riasis, other considerations may justify therapy according to individu-
al circumstances4. 
Combination treatment of PUVA and retinoids is also currently used 
to treat psoriasis4,36,37.
Classical systemic therapies
This section describes the current systemic treatments for psoriasis: 
methotrexate, cyclosporin, systemic retinoids and fumarates.
Methotrexate (MTX)
MTX is indicated for patients with severe psoriasis when topical treat-
ment and photo(chemo)therapy have been shown to be ineffective or 
contraindicated2,3.
 As a folic acid antagonist it competitively inhibits dihydrofolate 
reductase, an enzyme necessary for DNA synthesis. In addition it has 
important effects on pyrimidine and purine metabolism, resulting in 
anti-inﬂammatory effects, inhibition of T-cell mediated immune re-
sponses and abnormal rapid epidermal cell proliferation38,39. 
 MTX is administrated as oral treatment or, less frequently, as 
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subcutaneous, intramuscular or intravenous treatment. Administra-
tion can be in a single weekly dosage or divided in 3 doses over a 24-
hour period each week (Weinstein schedule). The maximum weekly 
single dosage, advised by the Dutch guideline, is 22,5 mg weekly2-4. 
Cyclosporin
Cyclosporin is a calcineurin inhibitor inhibiting the transcription 
and synthesis of various cytokines4,20. Such as MTX it is a ﬁrst-line
systemic treatment for severe psoriasis after conventional thera-
pies (topical treatment and/or photo(chemo)therapy) are ineffective 
or inappropriate2,3. The advised daily dosage by the guideline of the 
Dutch Society for Dermatology and Venereology is 3-5mg/kg, divided 
in a twice daily dosage2-4.
Systemic retinoids:acitretin
“Retinoid” is the family name of natural and synthetic analogues of 
vitamin A. These vitamin A analogues bind to the nuclear retinoid acid 
receptor (RAR). This complex, again, binds response elements at DNA 
level, resulting in anti-inﬂammatory and anti-proliferative effects4,5.
 Monotherapy with acitretin is effective in 30% of patients with 
chronic plaque psoriasis, and in erythrodermic and pustular psoria-
sis. Combination therapy with UVB and retinoids is possible4,5. 
 Treatment of psoriasis vulgaris with retinoids in combination 
with another therapy (topical corticosteroids, dithranol, tar, selective 
UVB phototherapy and PUVA), enhances therapeutic effectiveness 
and allows a lower retinoid dosage. Acitretin (Neotigason®) is the most 
prescribed retinoid4-6.  
Fumarates (Fumaderm®)
Fumaderm has not been registered in the Netherlands. Registration 
has been obtained in Germany, France and Switzerland. Data about 
the safety of fumarates are limited. The exact mode of action is un-
known but there is some evidence that fumarates restore the Th1 and 
Th2 cytokine balance4.
1.4.3 Biological therapies
Many patients are challenged to manage their disease for decades. 
However, the suitability of classical systemic treatments as continu-
ous long-term maintenance therapy is questionable and despite the 
efforts to optimize available treatments by various approaches (com-
bination, rotation, sequential, intermittent) in some ‘high-need’ pa-
tients, disease control is insufﬁcient. In those ‘high-need’ patients, the
biologicals may be able to provide a more consistent control of symp-
toms with conservation of a good safety proﬁle.
 Since 2004 the European Union has approved three biologic 
agents for the treatment of adult patients with moderate to severe 
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plaque psoriasis who failed to respond to, or have a contraindica-
tion to, or are intolerant of other systemic therapies. These biologic 
agents are: etanercept (Enbrel®), efalizumab (Raptiva®) and inﬂixi-
mab (Remicade®). The registration of a fourth biological, adalimumab 
(Humira®) is expected to occur at the end of 2007. In the United States 
alefacept has been registered since 2004 for treatment of psoriasis. 
Short-term data suggest that these agents are safe and mainly mild 
adverse events have been reported so far. However, long-term safety 
data over many years are still largely unknown.
 There are two major targets of the biologicals available so far: 
TNF-α (etanercept, adalimumab and inﬂiximab) and T-cells (efalizu-
mab, alefacept).
Anti-TNF-α agents
TNF-α
TNF-α is a cytokine mainly produced by macrophages but also by a 
variety of other cells such as lymphoid cells, mast cells, endothelial 
cells and ﬁbroblasts. It promotes an inﬂammatory response that in
turn induces many of the clinical problems of psoriasis. There are 
two distinct TNF Receptors (TNFR): a soluble form and a cell surface 
receptor40.
Etanercept
Etanercept is a fusion protein produced by recombinant DNA technol-
ogy. This fusion protein consists of the extra-cellular ligand-binding 
portion of the human tumour necrosis factor receptor and the Fc por-
tion of human IgG1. It is a soluble form of the TNF receptor and can 
bind to two soluble TNF molecules thereby blocking their interaction 
with cell surface TNF-α receptors41-43. 
 Etanercept is administrated subcutaneously 25 or 50 mg twice 
weekly. The European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA) label advises to start on 50 mg etanercept twice weekly 
the ﬁrst 3 months and to continue treatment with a reduced dosage of
25 mg biweekly41-46. 
 At week 12, 34% and 49% of patients receiving etanercept 
25mg biweekly and 50 mg twice weekly, respectively, a reduction of at 
least 75% in pre-treatment PASI score (PASI-75) was achieved. At the 
same time point and dose levels, 58% and 74%, respectively, achieved 
PASI-5041-46.
 Studies have shown that response is maintained after this dos-
age reduction and is not followed by deterioration in disease control. 
Forty nine percent of patients reached a PASI-75 at week 12 on 50mg 
of etanercept biweekly, while 54% of patients achieved a PASI-75 at 
week 24 following a dosage reduction for a further 12 weeks to 25mg 
etanercept biweekly41-46. 
 If PASI improvement is less than 50% after 3 months, etaner-
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cept should be discontinued. Also, due to limited data on the safety of 
continued treatment, a maximum duration of 24 weeks of treatment 
has been advised by the EMEA. Retreatment, however is possible.
Inﬂiximab
Inﬂiximab (Remicade®) is a chimeric (combination of mouse and hu-
man components) monoclonal antibody. It binds both membrane-
bound and soluble forms of TNF-α.
 Inﬂiximab administration is by intravenous infusion, 5mg/kg
at week 0, 2, 6 followed by 2 month intervals with good results: 88% of 
patients reaching a PASI-75 and 97% of patients reaching a PASI-50 
by or before week 10 have been reported42-46.
Adalimumab
Adalimumab is a fully human IgG1 monoclonal antibody produced by 
recombinant DNA technology in a mammalian cell expression system 
and binds speciﬁcally to TNF-α. As a consequence the interaction be-
tween TNF-α and its two distinct receptors is blocked. Adalimumab 
should also be administrated subcutaneously. It has not been regis-
tered for psoriasis yet but registration is expected soon.
 The results of a phase II, double-blind, placebo-controlled 
study in 149 adults patients with moderate-severe psoriasis showed a 
PASI-75 improvement in 77% of the patients receiving 40 mg subcuta-
neously weekly and in 67% of the patients receiving 40 mg subcutane-
ously every other week at week 24. In another recent study in which 
patients were treated with adalimumab 40 mg subcutaneously every 
other week, 67% and 56% showed a PASI-50 and PASI-75, respec-
tively, after 12 weeks42,43,45,47.  
Anti-T-cell agent
Efalizumab
Efalizumab (Raptiva®) is an immunosuppressive, recombinant hu-
manized monoclonal IgG antibody. It binds to the T-cell surface mol-
ecule CD11a, the α-subunit of leucocyte function-associated antigen-
1 (LFA-1). This in turn inhibits the interaction between LFA-1 and 
intracellular adhesion molecule 1 (ICAM-1) thereby inhibiting T-cell 
activation, trafﬁcking of T-cells from the circulation into the skin and
reactivation of T-cells.
 Efalizumab is administered by a subcutaneous injection once 
a week with an initial dosage of 0.7mg/kg followed by 1.0mg/kg once 
a week. Treatment with efalizumab should only be started in patients 
with stable chronic plaque psoriasis. 
 About 27% and 59% of patients reach a PASI-75 and PASI-50, 
respectively at 3 months of therapy. However, PASI response rates 
have proven to continue to improve from weeks 12-24 with 44% and 
67% reaching a PASI-75 and PASI-50, respectively after 24 weeks of 
continuous treatment42,43,45,46,48.
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Alefacept (Amevive®)
Alefacept is, like etanercept a fusion protein, produced by recombinant 
DNA technology. It consists of the extracellular CD2-binding portion 
of the human leukocyte function antigen-3 (LFA-3) linked to the Fc 
portion of human IgG1. Alefacept inhibits activation of CD2, CD4 and 
CD8 positive T-cells, which stimulate hyperproliferation of keratinoc-
ytes. 
 Possible routes of administration are intravenously or intra-
muscularly with a standard dosage regimen of weekly application of 
7,5 mg iv or 15mg im for 12 weeks. Alefacept has been registered in 
Canada, the United States, Australia, Switzerland and Israel for the 
treatment of adult patients with moderate to severe psoriasis who are 
candidates for systemic treatment4,42,43. 
So far, it has not been approved by the EMEA.
1.5 Limitations of the available anti-psoriatic 
 treatments
All treatments have limitations with respect to efﬁcacy, safety and tol-
erability. 
1.5.1 Limitations of topical treatments
Coal tar
Immediate limitations of tar include messiness, unpleasant smell and 
staining, irritant, allergic and phototoxic responses and folliculitis. As 
tar has a well established carcinogenic potential, long-term toxicity of 
coal tar products is a concern4,5.
Dithranol
Short-term side effects include irritation and staining of the skin, 
nails and clothes, which is a serious limitation of this time honoured 
principle4,5. 
Corticosteroids
According to the guideline of the Dutch Society of Dermatology and 
Venereology, in adults to prevent the development of side effects, class 
II and III topical corticosteroids should be applied with a maximum of 
100 grams weekly and class IV corticosteroids with a maximum of 50 
grams weekly1,2,20. 
 Possible side effects are: skin atrophy, striae, teleangiectasia, 
vascular dilatation, purpura, hypertrichosis, acneiform eruptions and 
hypopigmentation. If patients use more than the maximally allowed 
quotations of class III or class IV corticosteroids patients are at risk for 
suppression of the pituitary-adrenal axis4,5,20.
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Vitamin D3 derivatives
Vitamin D3 analogues have a limited toxicity but cause skin irritation 
in up to 30% of the patients and disturbance in calcium metabolism 
when more than 100 grams of calcipotriol ointment/cream/week or 
210 grams of calcitriol ointment a week is used4,5,20.
Calcineurin inhibitors
Long-term safety data on calcineurin inhibitors are not available yet. 
Well-known immediate side effects are burning sensation at the site of 
application, erythema, irritation, hyperesthesia, paresthesia, folliculi-
tis and pain. The efﬁcacy is limited to ﬂexural and facial psoriasis20.
Topical retinoid: tazarotene
Side effects observed using tazarotene are irritation, burning, pruri-
tus, erythema and desquamation within and peripheral to the lesion 
where this has been applied. To avoid teratogenic side effects of topical 
tazarotene, no more than 20% of the body surface should be treated 
with it31.
1.5.2 Limitations of photo(chemo)therapy
The most common short-term side effects of photo(chemo)therapy are 
erythema and sunburn and also pruritus in case of PUVA therapy. Of 
most concern is the long-term risk of carcinogenicity4. 
1.5.3 Limitations of systemic treatments
Methotrexate (MTX)
Common side effects of MTX are gastro-intestinal symptoms, nausea 
and abnormal liver function tests. Other known side effects are my-
elosuppression inducing leukopenia, thrombocytopenia and rarely, 
folate-deﬁcient megaloblastic anaemia20,49. Based on studies and clini-
cal experience, prescription of folate supplementation is advised for 
every patient receiving MTX2,3,50. 
 Hepatotoxicity, including liver ﬁbrosis and cirrhosis, is a major
concern and restricts use of MTX in psoriasis. Early studies showed 
a very high prevalence of up to 50% liver ﬁbrosis and up to 20% liver
cirrhosis in psoriatic patients using MTX51. However, recent literature 
suggests that MTX-associated liver damage is less prevalent than pre-
viously assumed38,49,52,53. 
 Concerns about this hepatotoxic injury have led to dermatolog-
ic guidelines that stipulate monitoring patients treated with MTX by 
liver histology periodically after every 1500 mg cumulative dose. Until 
now liver biopsy is considered the gold standard method to assess the 
histological changes, but its application is complicated by some limi-
tations. A liver biopsy is an invasive procedure and can be a burden 
to the patient. Complications occur in 1-2% of the patients including 
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pain, localized bleeding, less often pneumothorax, haemothorax, bile 
peritonitis, haemobilia, and inadvertent puncture of the kidney or in-
testine. Another limitation of the liver biopsy is the possible chance for 
sampling error49,54,55.
Fear for developing liver injury and the liver biopsy procedure make 
the dermatologist and the patient more reluctant to choose MTX as a 
treatment alternative. 
Cyclosporin
The most important side effects of cyclosporin are dose-related and 
sometimes irreversible nephrotoxicity and hypertension. These side 
effects demand regular monitoring of blood pressure, renal function 
tests and treatment for only several-month courses (maximally one 
year). Other side effects include increased risk of cutaneous and sys-
temic malignancy (especially in psoriasis patients previously treated 
with high-dose UV irradiation), tremor, altered liver function tests 
and gastrointestinal intolerance, elevated potassium and uric acid 
levels, decreased serum magnesium, mild normochromic normo-
cytic anaemia, gum hyperplasia, hypertrichosis, acral paraesthesia or 
hyperaesthesia4.
Systemic retinoids: acitretin
The most concerning side effect is its teratogenicity demanding women 
to avoid pregnancy within 2 years following treatment with acitretin. 
Furthermore, extraossal hyperostosis and hyperlipidaemia are a seri-
ous concern4.
Fumarates
Known side effects of the fumarates are renal impairment, ﬂushing,
gastrointestinal disturbances, headache and fatigue. Here also, regu-
lar blood analysis of liver, kidney and haematological parameters is 
advised4.
1.5.4 Limitation of biological therapies
Anti-TNF-α
Most common side effects of anti-TNF-α are injection side reactions 
and mild infections. Nevertheless, allergic reactions to etanercept, an 
increased risk for developing serious and especially opportunistic in-
fections like tuberculosis, aggravation of an existing heart failure, de-
myelinating conditions and malignancies all have been reported dur-
ing the treatment with anti-TNF-α agents41-43,45.
Anti-T-cell agent
In case of efalizumab ﬁrst dose reactions are common including head-
ache, fever, nausea, chills, myalgia within two days following the ﬁrst
two injections. Furthermore, patients might be at increased risk for 
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developing infections. In case of instable chronic plaque psoriasis, 
worsening of the psoriasis has often been seen. Other serious adverse 
events that have been reported during the treatment with efalizu-
mab were malignancies, thrombocytopenia, arthritis and haemolytic 
anemia38,42,43,45,56.
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1.6 Aims of this thesis
The studies carried out in this thesis are an attempt to optimize the 
available antipsoriatic treatments with respect to safe disease con-
trol. 
Aim I: An increased efﬁcacy/safety ratio of topical treatments will
decrease the population of psoriatic patients requiring systemic treat-
ments. Clinical evidence is available that the combination of vitamin 
D3 and corticosteroids is the most effective principle for topical treat-
ment. Formulations of both compounds are available which are highly 
acceptable to the patient for use in daily life. 
A study was planned to understand the improved efﬁcacy of a com-
bination therapy of calcipotriol and betamethasone dipropionate 
in terms of effects on T-cell subsets and epidermal proliferation 
and differentiation.  
Aim II: A limitation of the classical systemic treatments for psoriasis 
is the cumulative toxicity potential. Methotrexate is the ﬁrst line sys-
temic treatment according to the guidelines of the Dutch Society for 
Dermatology and Venereology. Hepatotoxicity is an important hazard 
of this treatment. 
We will set out a study to deﬁne the degree of methotrexate-in-
duced hepatoxicity and to develop new strategies for monitoring 
this hepatotoxicity. 
Aim III: Biologicals have been introduced in the treatment of psoria-
sis in 2005. A prospective evaluation was carried out with respect to 
the introduction of routine care with biologicals. 
In order to evaluate the efﬁcacy and safety of biologicals in rou-
tine care, a special unit and a database were set up. High-need 
psoriasis patients were treated at this unit with biologicals to 
provide best possible care.
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Classical topical treatments remain to be the ﬁrst line approach in the
management of psoriasis. In fact 60% of the population of psoriatic 
patients has mild-moderate disease. Improvement of the efﬁcacy/safe-
ty ratio of topical treatments implies that systemic treatments and bio-
logicals more and more are restricted to patients with severe disease. 
Various clinical studies have shown that the combination of calcipo-
triol and betamethasone dipropionate is a major improvement with 
increased efﬁcacy beyond efﬁcacy of monotherapies. The question re-
mains, however, what the mechanistic rationale for this improved ef-
ﬁcacy is.
We set out a study to understand the improved efﬁcacy of a combina-
tion therapy of calcipotriol and betamethasone dipropionate in terms 
of effects on T-cell subsets and epidermal proliferation and differentia-
tion.
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Chapter
How to improve monitoring 
of liver toxicity in patients 
treated with Methotrexate
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Chapter 3 is about MTX hepatotoxicity. As written before, fear for de-
veloping liver injury and the liver biopsy procedure make the derma-
tologist and the patient more reluctant to choose MTX as a treatment 
alternative. However, MTX has proven to be effective and it will con-
tinue to play an important role in the treatment of psoriasis. This, plus 
the fact that studies vary widely with respect to prevalence of MTX-
induced liver injury underline the importance of further research in 
this area.
First of all a survey was conducted among dermatologists and resi-
dents in dermatology to document their adherence to the guideline of 
the Dutch Society of Dermatology and Venereology with respect to the 
treatment with MTX for severe chronic plaque psoriasis.  The results 
of this survey, together with the wide variation in prevalence of MTX-
induced liver injury in psoriasis found in literature and the known 
restrictions of a liver biopsy led to another study evaluating the preva-
lence and development of liver injury in MTX treated psoriasis.
Until now, the gold standard to monitor liver injury is a liver biopsy. 
Complications of this liver biopsy restrict its clinical use. Therefore, 
there is a pressing need for non-invasive, reliable alternative methods 
to monitor MTX-induced liver injury in psoriasis patients. In this thesis 
a pilot study was carried out, evaluating the accuracy and feasibility 
of the Fibroscan® and Fibrotest, two novel, non-invasive methods that 
might be able to assess MTX-induced hepatic ﬁbrosis in psoriasis pa-
tients. Despite the results of this and other studies searching for alter-
natives, the liver biopsy is still inevitable in many cases. Although liver 
damage is graded according to the Roenigk classiﬁcation, the Roenigk
classiﬁcation itself is subjective and insensitive to small changes, par-
ticularly when assessing ﬁbrosis; lumping all biopsies with more than
minimal ﬁbrosis as advanced ﬁbrosis. Furthermore, this classiﬁcation
has never been validated and no literature is known about the inter-
observer reliability. Since the assessment of liver damage is essential 
in the management of psoriasis patients the results of the Roenigk 
scoring system should be reproducible with little inter-observer error. 
Therefore a study was performed determining the inter-observer reli-
ability of the Roenigk score as classiﬁcation system of liver damage
and its possible consequences for clinical practice.
How to improve monitoring of liver toxicity in
patients treated with Methotrexate
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 Introduction 
 Methotrexate (MTX) is an established and relatively 
inexpensive treatment for severe psoriasis. Concerns 
about the potential danger of toxicity have prompted the 
development of guidelines for monitoring patients re-
ceiving MTX  [1–4] .
 In 2003, the Dutch guideline ‘Photo(chemo)therapy 
and systemic therapy for severe chronic plaque psoriasis’ 
was established. The aim of this guideline was to sum-
marize the scientific background of current systemic 
therapies for moderate to severe psoriasis and, based on 
a systematic literature review, to give evidence-based rec-
ommendations for daily practice for Dutch dermatolo-
gists. In this way a guideline for the treatment of psoriasis 
is available for dermatologists, taking into consideration 
the efficacy, side effects and the burden for patients, in 
order to give the best care available. The Dutch guideline, 
as evidence-based guideline, can be regarded as represen-
tative of the currently available national guidelines in 
other countries.
 To the Committee Psoriasis of the Dutch Society of 
Dermatology and Venereology the question raised how 
closely this guideline is followed in clinical practice 
while treating patients with MTX. To investigate this, 
the Department of Dermatology of the Radboud Univer-
 Key Words 
 Methotrexate  � Guideline, Dutch Society of Dermatology 
and Venereology  � Psoriasis 
 Abstract 
 Background: In 2003, the Dutch guideline ‘Photo(chemo) 
therapy and systemic therapy for severe chronic plaque pso-
riasis’ was established.  Objectives: To document how close-
ly this guideline is followed in clinical practice with respect 
to the methotrexate (MTX) treatment and to formulate rec-
ommendations to adjust the guideline.  Methods: A survey 
was conducted among Dutch dermatologists and residents 
in dermatology. The questionnaire assessed the knowledge 
of and the adherence to the guideline with respect to MTX 
treatment.  Results: Fifty percent of the contacted derma-
tologists/residents responded. Fifty-two percent follow the 
guideline with respect to MTX. Liver biopsy and the frequen-
cy of blood investigations cause a discrepancy between 
guideline and reality. There is a lack of consensus between 
guidelines of the different specialisms concerning liver bi-
opsy.  Conclusion: The need for liver biopsies in combination 
with the frequent check-ups and the lack of consensus be-
tween rheumatologists, hepatologists and dermatologists 
seem to restrict the adherence to the guideline. 
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sity Medical Centre Nijmegen, The Netherlands, in con-
junction with the Committee Psoriasis of the Dutch So-
ciety of Dermatology and Venereology, conducted a sur-
vey among Dutch dermatologists and residents in 
dermatology.
 This publication describes the adherence of the Dutch 
dermatologist to the guideline ‘Photo(chemo)therapy and 
systemic therapy for severe chronic plaque psoriasis’, in 
relation to the treatment of patients with MTX. These re-
sults together with an update of the recent literature may 
lead to recommendations to adjust the guideline with re-
spect to treatment with MTX. Because of the resemblance 
to the international guidelines, these results may, at least 
to some extent, be applicable to other countries.
 A summary of the American, British and Dutch guide-
lines is drawn in  tables 1 ,  2 and  3 .
 Methods 
 Questionnaires were sent to 448 Dutch dermatologists and 
residents. The names were selected from the membership direc-
tory of the Dutch Society of Dermatology and Venereology.
 Questionnaire 
 The interview included professional characteristics of the der-
matologists such as function (dermatologist or residency pro-
gramme), years of experience and type of their practice (academ-
ic or peripheral hospital). The second part of the survey focused 
on MTX treatment for psoriasis patients such as the estimated 
number of patients with psoriasis they treated and whether or not 
they currently use MTX therapy. Furthermore detailed questions 
were asked on MTX prescribing such as their considerations re-
garding the decision to start MTX, baseline and follow-up liver 
Table 1. MTX in psoriasis; revised guidelines of the American 
Academy of Dermatology
1 Pre-MTX evaluation
a CBC count with differential count
b Serum creatinine, blood urea nitrogen, urinalysis,
creatinine clearance
c AST, ALT, alkaline phosphatase, bilirubin, albumin,
hepatitis A, B and C serology
d HIV antibody determination in patients at risk for AIDS
2 Early-treatment (2–4 months) liver biopsy should be consid-
ered if any of the following risk factors are present to a signifi-
cant degree:
a History of or current excessive alcohol consumption
b Persistent abnormal liver chemistry studies
c History of liver disease including chronic hepatitis B or C
d Family history of inheritable liver disease
e Diabetes mellitus
f Obesity
g History of significant exposure to hepatotoxic drugs or 
chemicals
3 Continuing laboratory studies
a CBC count with differential and platelet count weekly for 
2 weeks, biweekly for the next month, then approximately 
monthly depending on leucocyte count and stability of
patient
b Blood urea nitrogen and serum creatinine at 3- to
4-month intervals
c AST, ALT, alkaline phosphatase and albumin every 4–8 
weeks (more frequent liver chemistry monitoring in lieu 
of initial liver biopsy)
4 More frequent monitoring may be useful in the following
circumstances:
a During initial treatment
b When increasing dose
c During episodes of increased risk of raised MTX blood 
levels (e.g. dehydration, impaired renal function, increased 
concomitant medications such as NSAIDS)
5 Liver biopsy is recommended after a cumulative MTX dose of 
approximately 1.5 g and thereafter at 1.0- to 1.5-gram
intervals
Adapted from Saporito and Menter [3].
Table 2. MTX in psoriasis: guidelines of the British Association 
of Dermatologists
1 Pre-MTX evaluation
a CBC with differential count
b Urea and electrolytes (sodium, potassium, creatinine)
c Liver function tests: AST, ALT, alkaline phosphatase,
bilirubin, albumin, total protein, hepatitis A, B and C
serology
d Chest X-ray (unless done within the last 6 months)
e PIIINP prior to starting MTX
2 Early-treatment (3–4 months) liver biopsy should be consid-
ered if there is a history of pre-existing liver damage
3 Continuing laboratory studies
a FBC, urea and electrolytes and liver function tests fort-
nightly for the first 6 weeks after the last dose change, 
thereafter monthly until stabilized; monitoring can be
reduced further, in discussion with the patient, to
3-monthly if the dose and trend remains stable
b PIIINP every 2–3 months
4 Liver biopsy should be considered for patients with
a Elevation of pre-treatment PIIINP above 8.0 g/l
b Elevation of PIIINP above normal range (1.7–4.2 �g/l)
in at least 3 samples over a 12-month period
c Elevation of PIIINP above 8.0 �g/l in 2 consecutive
samples
PIIINP = Aminoterminal propeptide of procollagen type III.
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biopsies and blood tests. The last part focused on their opinion 
about the guideline and their recommendations.
 Questions were both open and closed and a combination of 
these two.
 Processing the Questionnaire 
 To some questions several answers were possible. The answers 
to the open questions were divided into categories. For example, 
in case of question 6 the categories were denominated corre-
sponding to the categories of the guideline: severe, therapy-resis-
tant, chronic plaque psoriasis (I1), pustular psoriasis (I2) and 
erythrodermic psoriasis (I3). Answers which were not (complete-
ly) in conformity with the categories in the guideline were as-
signed to the category I4. A category I5 was established for the 
remaining answers.
 Results 
 Questionnaires were received for data analysis from 
223 dermatologists or residents in dermatology (50% re-
sponse rate). Six dermatologists were not in clinical prac-
tice and were excluded from further analysis. Of the re-
mainder, 179 were completed by dermatologists and 38 
by residents in dermatology. Fourteen of them were not 
involved in treatment of psoriasis patients. Another 40 
dermatologists did not currently prescribe MTX (26 of 
them had prescribed MTX before). Hundred-sixty-three 
questionnaires were suitable for analysis.
 Guideline 
 Eighty-nine percent of all respondents were aware of 
the MTX guideline. Ten percent did not know about the 
existence of this guideline. From 1%, no answer was re-
ceived.
 MTX for Psoriasis 
 Thirty-nine percent of the respondents prescribe 
MTX in case of a severe, therapy-resistant, chronic 
plaque psoriasis (I1), 2% in case of pustular forms of 
psoriasis (I2) and 1% in case of erythrodermic forms of 
psoriasis (I3). Sixty-three percent of them reported the 
use of criteria that approximate but not completely meet 
those of the guideline (I4; methods) and 31% noticed 
considerations that have not been mentioned in the 
guideline (I5), for example psoriatic arthritis, high age, 
kidney disturbances, compliance and functional com-
plaints.
 Three quarters of the dermatologists and residents 
never prescribe MTX in case of certain risk factors. Usu-
ally this is the case with absolute contra-indications but 
sometimes also in case of relative contra-indications. A 
small percentage (5%) always prescribes MTX, also when 
contra-indications are present ( fig. 1 ).
 Baseline Biopsies 
 Most of the respondents (82%) never order a baseline 
biopsy routinely before starting MTX treatment; 3% al-
ways does. Fifteen percent (15%) order a baseline biopsy 
for patients with risk factors ( fig. 2 ). Risk factors reported 
are: liver function test abnormalities, alcohol abuse, signs 
of liver pathology provided by ultrasound or anamnesis, 
hepatotoxic medication and liver pathology in the past.
 Most (59%) of the 29 physicians who always, or in case 
of risk factors, request a baseline liver biopsy, indicate to 
do this after 3 months of treatment. The remainder re-
quest it before MTX treatment.
Table 3. MTX in psoriasis: guidelines of the Dutch Society of Der-
matology and Venereology
1 Pre-MTX evaluation
a CBC with differential count
b Serum creatinine, urea, urinalysis, creatinine clearance
c AST, ALT, alkaline phosphatase, G-GT, albumin,
bilirubin, LDH, hepatitis B and C serology
d Pregnancy test
e Chest X-ray
f Liver echo
2 Early-treatment liver biopsy should be considered if any of 
the following risk factors are present to a significant degree:
a History of or current excessive alcohol consumption
b Persistent abnormal liver chemistry studies
c History of liver disease including chronic hepatitis B or C
d Family history of inheritable liver disease
e Diabetes mellitus
f Obesity
g History of significant exposure to hepatotoxic drugs or 
chemicals
3 Continuing laboratory studies
a CBC count with differential and platelet count at weeks 1, 
2 and 4 and then every 4–8 weeks
b Liver function tests: 3 days after starting MTX, thereafter 
every 4–8 weeks (AST, ALT, AP and albumin)
c Serum creatinine and creatinine clearance at 3-month in-
tervals; creatinine clearance only in case of special reasons
d Urinalysis
4 More frequent monitoring may be useful in the following
circumstances:
a When increasing dose
b During episodes of increased risk of increased MTX blood 
levels (e.g. dehydration, impaired renal function,
increased concomitant medications such as NSAIDS)
5 Liver biopsy
a Liver biopsy is recommended after a cumulative MTX 
dose of approximately 1.5 g and thereafter at 1.5-gram
 intervals
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 Seventy-two percent of the respondents who let per-
form a baseline liver biopsy stop or do not start prescrib-
ing MTX when an abnormality has been found in the 
histology, usually in case of Roenigk grade  [5] IIIa or IV 
liver histology according to the Roenigk classification. 
Others continue prescribing MTX in case of an abnormal 
liver biopsy but request follow-up liver biopsies more fre-
quently. Ten percent more frequently determine the liver 
enzymes. Most of them did not mention a Roenigk 
grade.
 Most of the dermatologists and residents (72%) who 
request a baseline liver biopsy also take into account 
other factors when drawing conclusions from an abnor-
mal baseline liver biopsy. Some of these are: alcohol in-
take, diabetes mellitus, obesitas, severity of the psoria-
sis, possible alternative treatments, the patient’s prefer-
ence, presence of hepatotoxic co-medication, the opinion 
of the hepatologist, the existence of arthritis and com-
pliance.
 Sixty-six percent did not see any life-threatening 
complications attributable to a baseline liver biopsy. Six 
physicians did not answer the question at all. The re-
maining respondents reported life-threatening compli-
cations in 1–5% of the patients, attributable to a baseline 
biopsy.
 Regular Monitoring of Blood Count 
 A great part of the respondents (83%) screen blood, 
liver enzymes and renal function during MTX treatment 
( fig. 3 ).
 Follow-Up Biopsies 
 Forty-four percent order follow-up biopsies during 
MTX treatment, the remainder does not. Reasons for the 
latter are: they reduce or withdraw MTX in case of abnor-
mal liver enzymes or a cumulative dosage of 1,5 g. Also, 
a liver biopsy may have complications or is too demand-
ing for the patient. Other reasons could be: a liver biopsy 
is not useful according to the rheumatologists, hepatolo-
gists refuse to carry them out, or laboratory results and 
an ultrasound are felt to give enough information 
( fig. 4 ).
 Just over two thirds of the respondents who request a 
follow-up biopsy do this after a cumulative dosage be-
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tween 1 and 6 g. Others ask for a biopsy in case of abnor-
mal liver function tests. Few respondents order a follow-
up biopsy in case of risk factors, aberrant pathological 
histology of the baseline biopsy or after a period of MTX 
therapy, an abnormal ultrasound, as well as advice of the 
hepatologist and/or rheumatologist ( fig. 5 ).
 In case of an abnormal follow-up biopsy, 66% of the 
dermatologists/residents withdraw the MTX treatment. 
Forty-seven percent of the dermatologists indicate to stop 
at Roenigk grade IIIb–IV. Thirty-two percent would re-
quest liver biopsies more frequently. Most of them (57%) 
feel to do so at Roenigk IIIa.
 When drawing conclusions following an abnormal 
follow-up liver biopsy, 44% of the respondents take into 
account the same factors as in the case of a baseline bi-
opsy.
 When certain abnormalities in a liver biopsy should 
lead to withdraw MTX according to the guideline, 10% of 
the responders might nevertheless continue the treat-
ment occasionally, for example in case of a severe psoria-
sis with no possible alternative treatment. This will hap-
pen in consultation with the hepatologist or in case the 
patient insists on it. However, the majority never contin-
ues MTX treatment in case of related pathology in a liver 
biopsy ( fig. 6 ).
 Guideline 
 Of those who are aware of the guideline, 52% follow 
it strictly, except for a liver biopsy. Reasons for this are: 
possible complications of a liver biopsy, inconvenience 
for the patient, refusal by the patient, diminished neces-
sity in case of a lower weekly dosage of MTX and lack of 
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concordance with the rheumatologists’ and the hepa-
tologists’ guideline. A number of dermatologists and 
residents find the guideline too strict, too defensive and 
too dogmatic. The check-ups are too frequently sched-
uled and therefore too intensive for the patient ( fig. 7 ).
 Most of the respondents (63%) are positive about the 
guideline ( fig. 8 ). Thirty-three percent would like to see 
some improvements. For example, they prefer the guide-
line to be more practical and simplified, with fewer check-
ups. The most frequently given criticism of the guideline 
is that they would like to see some changes in relation to 
liver biopsy. For example, a follow-up liver biopsy should 
not be requested according to a strict schedule. Finally 
they would like to see more consensus between the hep-
atologist’s, rheumatologist’s and dermatologist’s manage-
ment of liver biopsies.
 Discussion 
 The aim of the survey was to investigate how closely 
the Dutch guideline ‘Systemic therapy for severe chronic 
plaque psoriasis’ is followed by Dutch dermatologists in 
clinical practice during the treatment of psoriasis pa-
tients with MTX.
 Years ago the Committee Guidelines established the 
working group ‘Psoriasis’ and formulated the quality,
extent and form of requirements for the guideline 
‘Photo(chemo)therapy and systemic therapy for severe 
chronic plaque psoriasis’. Then, during 2 public member 
meetings of the NVDV (Nederlandse Vereniging voor 
Dermatologie en Venereologie), the definitive guideline 
was discussed, accepted in 2003 and finally published in 
2003 and 2004  [2, 4] . Besides the published guideline, the 
guideline can also be found on the website of the NVDV 
(www.huidarts.info).
 The present survey shows that 11% of the dermatolo-
gists are not well informed about the guideline. On the 
other hand, 89% know about the guideline and the ma-
jority of them (80%) actually uses it in their clinical 
practice. However, the need for liver biopsies in combi-
nation with the frequent check-ups and the lack of con-
sensus between the different specialists in relation to 
liver biopsy seem to restrict the adherence to the guide-
line. The most important reasons to avoid a liver biopsy 
are: (1) the potential risks of the procedure; (2) the re-
luctance to prescribe MTX in the presence of (relative) 
contra-indications; (3) the lack of consensus between 
the rheumatologists, hepatologists and dermatologists 
in relation to liver biopsy; (4) the relatively short dura-
tion in which MTX is used, and (5) according to some, 
the opinion that the usefulness of a liver biopsy is not 
evidence-based.
 The generalizability of our findings to all Dutch der-
matologists and especially to those in other countries is 
uncertain. However, MTX retains a central role in the 
treatment of severe psoriasis in Europe  [1] and because of 
the resemblance to the international guidelines, our re-
sults may, at least to some extent, be applicable to other 
countries.
 The reported frequency of liver fibrosis and cirrhosis 
in liver biopsies of psoriasis patients on MTX treatment 
varies widely in different studies (fibrosis 1–50% and cir-
rhosis 0–20%)  [6–8] . This uncertainty about a delineated 
effect led to the recommendation of an intensive moni-
toring regime  [6] . However, MTX-induced liver cirrhosis 
seems to have a benign character and progresses only 
slowly  [9–11] . Also, a liver biopsy might not be represen-
tative because it samples only one 50,000th of the entire 
liver. The sampling error can approach 30%  [12] . Fur-
thermore, liver biopsy is by no means a popular investiga-
tion; performing a liver biopsy and histopathological in-
vestigation is relatively expensive, patients experience a 
liver biopsy as inconvenient and the results influence fur-
ther management only in a few patients  [13] .
 The limited adherence to the guideline in relation to 
liver biopsy has its roots in the reasons mentioned above. 
Whereas monitoring liver damage is perceived as very im-
portant when using MTX, it appears that the need for a 
liver biopsy, the gold standard to monitor liver damage, 
impedes the prescription of MTX. As a consequence it 
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seems very important to find an alternative for monitoring 
and detecting liver fibrosis and cirrhosis. This makes it 
necessary to develop non-invasive methods to detect and 
monitor liver fibrosis and cirrhosis. It has been shown that 
fibrosis can develop despite normal serum liver values and 
normal ultrasound and radioisotope scans. Liver scintig-
raphy seemed promising as a screening test, but it turned 
out not to be able to differentiate between the severer forms 
of liver damage like liver fibrosis and cirrhosis  [14] . Two 
recently published studies show that the values of amino-
terminal propeptide of procollagen type III (PIIINP) can 
be highly sensitive in detecting and monitoring liver fibro-
sis, although the serum PIIINP value is not organ-specific 
and may also be raised in children, adolescents and in var-
ious pathological states including inflammatory arthritis, 
scarring, scleroderma, myocardial infarction and hyper-
thyroidism  [12–14] . According to those studies liver biop-
sies can be avoided when serial PIIINP measurements 
(once per 3 months) are normal. In case of abnormal 
PIIINP values without other conditions associated with el-
evated PIIINP levels, a liver biopsy should be performed 
 [13, 14] . Performing a liver biopsy only in patients with an 
abnormal PIIINP resulted, according to the study of Mau-
rice et al.  [14] , in a 45% reduction of all liver biopsies and 
the study of Chal mers et al.  [13]  in a sevenfold reduction, 
without important liver damage being missed. Boffa et al. 
 [15]  and Zachariae et al.  [8, 16, 17]  also concluded that the 
chance to develop substantial liver fibrosis and the risks of 
missing significant liver damage are minimal in case of 
persisting normal PIIINP values.
 Of course, a limitation of our study is the fact that se-
lection bias may have affected our results; dermatologists 
interested in psoriasis and MTX were more likely to par-
ticipate in this survey. However, the response rate to our 
survey (49,8%) was at least as good as for similar surveys 
among dermatologists  [1, 18, 19] . Furthermore, 91% of 
the respondents currently prescribed MTX for psoriasis 
patients and 80% of them said to use the guideline in their 
clinical practice. These high numbers make the meaning 
of the results clearer. Furthermore, reimbursement of the 
expensive biologicals is restricted to ‘high-need’ psoriasis 
patients who may be defined using criteria that include 
disease severity and resistance and/or intolerance to a 
number of conventional therapies  [18] , like MTX. Also, 
in the future MTX will more and more be used in com-
bination with one of these biologicals. This will strength-
en the central role of MTX in the treatment of severe pso-
riasis in Europe.
 Conclusion 
 In conclusion, we would like to propose the following: 
it would be preferable to simplify the check-up schedule 
and make it more uniform for use, to achieve consensus 
between dermatologists, rheumatologists and hepatolo-
gists in relation to liver biopsy, to limit the number of 
liver biopsies by introduction of measurement of the se-
rum PIIINP value and finally find an alternative for the 
liver biopsy. Because of the resemblance to the interna-
tional guidelines, these results may, at least to some ex-
tent, be applicable to other countries. Of course, a critical 
investigation is needed to find out if a simplification of 
the check-up schedule is safe and advisable.
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SUMMARY
Background
Methotrexate-induced liver damage in psoriasis has led to dermatologic
guidelines that stipulate monitoring of liver injury by means of serial
liver biopsies. Recent literature data suggest that methotrexate may be
considerably less hepatotoxic than previously assumed.
Aim
To evaluate prevalence and development of liver injury in methotrexate
treated psoriasis.
Methods
Retrospective chart review (1976–2005).
Results
Hundred and twenty-ﬁve patients (F58/M67; mean age 45.0, SD
12.7 years) received a median cumulative methotrexate dose of 2113 mg
(range 180–20 235) over a median period of 228 weeks (range 16–1763).
Two hundred and seventy eight liver biopsies were analysed and 71%
were classiﬁed as Roenigk grade I, 14% as Roenigk II, 14% grade IIIa, 2%
grade IIIB and 2% grade IV. Liver injury was not associated with cumula-
tive dose, weekly prescribed dose, age or duration of treatment. Obesity
and diabetes were signiﬁcant risk factors for liver injury. A total of 68
patients had multiple biopsies, 3% improved, 72% did not change and in
25% liver histology deteriorated. The majority of cases (84%) that pro-
gressed to Roenigk 2 had a cumulative dose of 1500–6000 mg.
Conclusions
Methotrexate-related liver injury is less frequent than previously
thought and mostly occurred at cumulative dose of <6000 mg. Diabetes
and being overweight are signiﬁcantly correlated with liver injury.
Aliment Pharmacol Ther 24, 805–811
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INTRODUCTION
Methotrexate (MTX) is the most commonly prescribed
systemic therapy for severe psoriasis. MTX, a folate
antagonist, competitively inhibits dihydrofolate reduc-
tase, an enzyme necessary for methionine, purine and
thymidylate synthesis and, ultimately, DNA synthesis.
MTX possesses potent anti-inﬂammatory effects on
T-cell mediated immune responses as it inhibits pro-
liferation or induces apoptosis in activated T-cells
and blocks the abnormal rapid epidermal cell prolif-
eration, both responsible for the characteristic skin
lesions in psoriasis.1 Long-term, weekly low-dose
methotrexate therapy is associated with some serious
adverse reactions as myelosuppression, interstitial
pneumonitis and hepatoxicity. The pathogenesis of
MTX-induced hepatic damage is poorly understood,
but intra hepatocellular accumulation of a polygluta-
mated metabolite of MTX might be responsible for
liver toxic effects. Several studies have suggested that
a pre-existent liver disease, overweight, diabetes
mellitus (DM) or alcohol use carries an increased risk
of hepatotoxicity.2
Early studies in MTX treated psoriatic patients
reported a very high prevalence of hepatotoxicity with
ﬁbrosis occurring in up to 50% and cirrhosis in up to
20%.3–5 Concerns about liver injury in psoriasis
patients has led to dermatologic guidelines that stipu-
late monitoring periodically after every 1500 mg
cumulative dose, in order to identify liver injury by
means of serial liver biopsies. Liver biopsy is consid-
ered as the gold standard method in the assessment of
histological changes,6 but its application is complica-
ted by some important limitations. A liver biopsy is
an invasive procedure and carries inheritent side
effects such as pain and localized bleeding.7, 8 How-
ever, recent literature suggests that MTX might be sig-
niﬁcantly less hepatotoxic and reports that liver
ﬁbrosis and cirrhosis are notably less prevalent than
previously assumed.9, 10 These data suggest that
reconsideration of our current monitoring strategies
for patients on MTX may be warranted. Recent litera-
ture proposes that procollagen III aminopeptide (PI-
IINP) measurements may be of additional value in
some patients.11, 12
In the present study, we reviewed the clinical
details and liver biopsies of 125 patients on long-
term, low-dose MTX therapy for psoriasis seen in a
large tertiary referral centre from 1976–2005. Our
aim was to establish the prevalence of MTX-induced
liver injury and to delineate potential contributing
factors.
METHODS AND MATERIALS
Subjects
This study is a retrospective chart review over a period
between 1976 and 2005. The strategy we followed to
identify subjects was as follows. We identiﬁed records
of all patients who had had a liver biopsy from the
pathology ﬁles and searched for patients who were
known at the Department of Dermatology. Subjects
eligible for our study were all psoriasis patients,
receiving a weekly dosage MTX and underwent single
or serial follow-up liver biopsies for monitoring liver
injury.
The clinical records were scrutinized for details
regarding age and sex, duration and onset of MTX
therapy, cumulative dose at the time of liver biopsy,
maximum prescribed weekly dosages, date and reason
for MTX-discontinuation, information about the liver
biopsy and histological outcomes, presence of risk
factors for liver damage (DM, alcohol use and
obesity) and other relevant facts from the clinical
history. We also recorded laboratory and liver
enzyme test results; alanine transaminase (ALAT),
aspartate transaminase (ASAT), alkaline phosphatase
(AP), c-glutamyl-transpeptidase (c-GT), total bilirubin
level, platelets and leucocytes counts. Elevated levels
were deﬁned as those above the upper limit of
normal.
All information was entered in a computerized data-
base. Samples of obtained data were structurally veri-
ﬁed to achieve maximum data exactness.
The Department of Dermatology is a large referral
centre for psoriasis and we have implemented a mon-
itoring process that closely follows the US guidelines
for MTX treatment. Brieﬂy, pre-MTX evaluation
includes history and physical examination, laboratory
tests consisting of complete blood cell count with dif-
ferential and platelet count, renal function, liver
chemistry and a chest X-ray. In case signiﬁcant risk
factors are absent, a liver biopsy is not necessary until
the patient has been treated with 1.5 g of MTX. Mon-
itoring during MTX-treatment includes complete blood
cell count with differential and platelet count and
liver chemistry every 4–8 weeks, and renal function
every 3 months. A follow-up liver biopsy is recom-
mended after every 1.5 g MTX. If there is clinical
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suspicion of liver injury the patient should be referred
to a hepatologist.13
Histology
Percutaneous liver biopsy was performed via right
intercostal approach with local lidocaine anaesthesia.
The biopsy specimen was immersed in 2% formalde-
hyde and subsequently ﬁxed with parafﬁn. Haematox-
ylin and eosin-stained sections of liver tissue were
examined for steatosis, lobular and portal tract inﬂam-
mation, hepatocyte necrosis and nuclear variability.
A von Gieson stain for collagen was assessed for the
presence of pericellular and perivenular ﬁbrosis, as
well as the expansion of the portal tracts. All liver
biopsies, sampled as part of the monitoring process of
MTX-induced hepatic injury were, graded according to
the Roenigk classiﬁcation (Grade 1, normal tissue,
no/mild fatty change, no/mild nuclear pleomorphism,
no ﬁbrosis, mild portal inﬂammation; Grade 2, moder-
ate/severe fatty changes, moderate/severe nuclear ple-
omorphism, no ﬁbrosis, moderate/severe portal
inﬂammation; Grade 3a, mild ﬁbrosis, portal ﬁbrotic
septa, extending in the lobuli, portal tract enlarge-
ment; Grade 3b, moderate/severe ﬁbrosis; Grade 4 ¼
cirrhosis, regenerating noduli and bridging of the por-
tal tracts). We deﬁned a baseline biopsy when it had
been performed either at start of MTX treatment
and/or before reaching a cumulative dose of 600 mg.
Statistical analysis
Data from the computerized database were analysed
using SAS statistical software, version 8.2 (SAS Insti-
tute Inc, Cary, NC, USA). Frequency tables were provi-
ded for demographic and histological variables. Risk
factors for liver injury (presence of DM, overweight
and use of alcohol) were analysed over histology,
expressed as Roenigk classiﬁcation and dichotomously
analysed using Pearson’s chi-square analysis (Fisher’s
exact test was used where appropriate). The same pro-
cedure was used for deviant concentrations of liver
enzymes.
Percentage of patients with liver injury, deﬁned as
Roenigk classiﬁcation beyond 1, was plotted per
cumulative MTX dose, both for the total patient popu-
lation and subdivided by the risk factors, mentioned
above. Finally, discontinuation of therapy was also
analysed per cumulative dose of MTX treatment, using
the same type of plots.
RESULTS
Demographics
Hundred twenty-ﬁve-psoriasis patients (58 female
and 67 male) with an average age of 45 years
(s.d. ¼ 13) at start of MTX therapy underwent
one or more monitoring liver biopsies. Ninety-two
patients carried pre-existent risk factors for
MTX induced liver injury at time of the ﬁrst biopsy.
Thirty-nine patients (31%) were overweight (deﬁned
as body mass index >25 kg/m2). Some 49% of
patients (n ¼ 61) were consuming alcohol, and we
categorized 11 (8%) as excessive consumers (>14 U/
week). Nine patients (7%) had DM. Twenty-six of
them only had a baseline biopsy, fourty-seven had
only one or more follow-up biopsies and 19 had
both.
The median maximum prescribed weekly dosage
MTX was 12.5 mg/week (range 2.5–35 mg/week).
Patients received a median cumulative MTX dose of
2113 mg (180–20 235 mg) during a median follow-up
period of 228 weeks (range 16–1763 weeks).
The 92 patients with risk factors also received a
maximum prescribed weekly dosage MTX of 12.5 mg/
week (range 0–35) with a median cumulative MTX
dose of 2256 mg (0–20 235) during a median
follow-up period of 219 weeks (range 16–1763 weeks)
(this includes baseline biopsies).
Histology
Patients underwent between 1 and 9 (median 2) biop-
sies per person, and collectively 278 liver biopsies
were sampled during the study period. Fifty-six biop-
sies were performed at baseline. Table 1 lists the distri-
bution of the various Roenigk scores among all liver
biopsies taken as well as those taken at baseline.
Eighty-eight patients (71%) did not develop histologi-
cal abnormalities during treatment (Roenigk grade I),
18 patients (14%) had Roenigk grade II, 15 had (12%)
grade IIIa, two had (2%) grade IIIB and two (2%) had
grade IV. (Table 1.) Characteristics about the patients
without histological abnormalities during treatment
are shown in Table 2.
A total of 69 patients had two or more liver biop-
sies. Intra-individual comparison between ﬁrst and last
biopsy demonstrated that the histological ﬁndings
remained unchanged in 72%, improved in 3% of
patients but deteriorated in a further 25%.
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Table 1 also lists the distribution of Roenigk score
per risk factor. Those with overweight and/or DM had
higher Roenigk scores in comparison to patients with-
out risk factors. In contrast, we did not observe an
adverse effect of alcohol use on histological scores.
Association between cumulative dose MTX
and liver injury
We observed that histological progression to Roenigk
grade 2 or higher, mostly occured when the cumula-
tive MTX dose was between 1500 and 6000 mg.
Higher dosages did not lead to increased liver injury
as the prevalence of progression to a higher Roenigk
score levelled beyond a cumulative MTX dosage of
6000 mg (Figure 1.)
Risk factors, cumulative doses and development
of liver damage
Next, we assessed whether biopsies taken from patients
with risk factors (n ¼ 190) progressed faster to higher
Roenigk score in comparison to those biopsies from
patients without known risk factors (n ¼ 88) (Figure 2.)
The presence of obesity, and/or DMD led to progres-
sion to a higher Roenigk score (Roenigk grade >1), at
earlier cumulative MTX dosages, while alcohol did
not.
Table 1. Risk factors per Roenigk-score
Roenigk (%)
1 2 3a 3b 4 P*
(a) Liver biopsies
Baseline� biopsy (n ¼ 55) 44 (80) 8 (15) 2 (4) 0 1 (2) 0.11
Follow-up biopsy (n ¼ 223) 154 (69) 31 (14) 33 (15) 4 (2) 1(0,4)
Total biopsies (n ¼ 278) 198 39 35 4 2
(b) Patients
No risk factors (n ¼ 34) 29 (85) 5 (15) 0 (0) 0 0 0.19
Overweight (n ¼ 38)� 24 (63) 10 (26) 2 (5) 1 (3) 1 (3) 0.01
Alcohol use (n ¼ 62) 49 (79) 8 (13) 4 (6) 0 1 (2) 0.67
DM (n ¼ 9) 6 (67) 1 (11) 0 1 (11) 1 (11) 0.42
MTX, methotrexate; DM, diabetes mellitus.
* Chi-square: Roenigk ¼ 1 vs. Roenigk > 1 (Fisher’s exact where appropriate).
� Baseline ¼ cum dose MTX £ 600 mg.
� Missing values ¼ 20.
Table 2. Characteristics of
patients with no histologic
abnormalities during treatment
Patients without histologic
injury (n ¼ 88) (71%)
Median maximum weekly dosage MTX 12.5 mg (range 0–25)
Median cumulative dosage MTX 2352 mg (range 0–16722)
Median duration follow-up period 214 weeks (range )238–1761)
Risk factors
Alcohol 37
Alcohol > 14U/week 5
DM 8
Adipositas 25
MTX, methotrexate; DM, diabetes mellitus.
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Liver enzymes and histological changes
Next, we examined the effect of the Roenigk score on
the levels of four different liver enzyme tests (c-GT,
AP, ASAT and ALAT). We observed that a higher pro-
portion of patients who had had a liver biopsy with a
Roenigk classiﬁcation ‡2 had c-GT beyond the upper
limit of normal (Odds ratio 1.80; 95% CI 1.30–2.49)
(Figure 3.) This contrasted with ASAT and ALAT serum
concentrations that did not correlate with Roenigk
scores. On the other hand, patients with Roenigk ‡2
had signiﬁcantly higher AP and ASAT compared with
those with Roenigk ¼ 1, but values were well within
normal range. All other laboratory tests did not corre-
late with the histological ﬁndings.
Continuation of therapy
Sixty patients (48%) still continued MTX at the end of
the studied period. The remaining 52% (65 patients)
had stopped using MTX. Most often MTX was stopped
relatively early after initiation of MTX, and most
patients who had stopped did so at cumulative doses
of <5000 mg. (Figure 4). Three patients died during
therapy but no deaths were attributed to use of MTX
or liver disease related. Reasons mentioned for discon-
tinuation are summarized in Table 3.
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Clinical outcome
Biopsies
Pathology results have a limited effect on clinical treat-
ment. Fibrosis/cirrhosis (Roenigk ‡ 3a) was detected in
41 biopsies from 24 patients at some point during MTX
treatment. Despite these pathological ﬁndings, MTX
therapy was continued in 26/41 biopsies. Histological
results led to discontinuation in only 6/41 biopsies. In
only 9/41 biopsies, treatment was stopped regardless of
the results from pathological examination of the liver
biopsy. Repeated liver biopsy in Roenigk 3 patients was
useful in the clinical treatment.
Patients
In 16 patients, liver biopsy was repeated after ﬁnding
signiﬁcant abnormalities at earlier assessments (aver-
age of 14 months). Histology did not change in ﬁve,
while it improved in 10 patients (in ﬁve patients to a
stage without ﬁbrosis). The liver histology worsened in
a single patient.
DISCUSSION
One of our aims was to establish the prevalence of
MTX-induced liver injury because the large variation
in previous literature.2, 9, 10 In this substantial cohort
of 278 liver biopsies taken over 30 years MTX-induced
liver ﬁbrosis (‡Roenigk grade 3a) was only seen in
15% (19 patients) of our population. Progression to a
higher stage of liver injury mostly occurred at a
cumulative dose-range between 1500 and 6000 mg,
which translates to at least 2 years of MTX treatment
at 15 mg weekly. Progressive development of liver
damage was infrequent above 6000 mg MTX (after
about 8 years with 15 mg weekly) when patients have
proven to tolerate high cumulative dosages MTX with-
out previously obtaining pathological hepatic differ-
ences. In contrast to our data, others found that the
cumulative probability of developing advanced hepatic
ﬁbrosis doubled after 5000 mg.9, 10
We carefully monitored our patients for MTX
induced toxicity by regular liver biopsies. As such our
practice mirrors the international guidelines and as
such the data can be viewed as a ﬁeld study for imple-
mentation of these guidelines.13, 14 As a consequence,
it is unlikely that we missed patients who were treated
with MTX and actually developed MTX-hepatotoxicity.
Most long-term observational studies in rheumatoid
arthritis indicate that toxicities, rather than lack of
efﬁcacy, are the most common cause of discontinuing
MTX.15 This appears to be in contrast with the situ-
ation in psoriasis. We and others found that low-dose,
long-term MTX treatment seems to be relatively safe
and effective, and that undesired side effects lead to
discontinuation in a minority.16
Another aim of our study was to delineate poten-
tial contributing factors to the development of
MTX-induced liver injury. Risk factors play an import-
ant role in the development of liver ﬁbrosis. At any
given cumulative MTX dosage, patients with obesity
and or DM had a signiﬁcantly worse liver histology
compared with patients without these risk factors. The
presence of fatty inﬁltration (steatosis) of the liver is
highly prevalent among obese and or diabetic patients,
and probably plays a role. This reminds us of the situ-
ation in non-alcoholic steatohepatitis (NASH) where
the presence of steatosis is associated with hepatitis
with necroinﬂammation and pericellular ﬁbrosis.17
Indeed, a recent case series showed that the presence
of NASH in psoriatic patients contributes to the
hepatotoxicity of MTX.18 These data suggest that his-
tological monitoring of MTX toxicity could be tailored
to obese patients with or without DM. Other research-
ers have emphasized the role of alcohol consumption
as a risk factor for MTX-induced ﬁbrosis.10 Surpris-
ingly, we could not conﬁrm this ﬁnding in our study
and is possible that the association is indeed absent in
our cohort. On the other hand, the retrospective nature
of our study carries inherent limitations, which may
hamper the interpretation of the data on alcohol use.
The retrospective nature of our study could have resul-
ted in the under-reporting of risk factors. But even so,
we found a signiﬁcant correlation between the per-
centage of patients with liver disease and the presence
of any risk factors. On the other hand, we cannot rule
Table 3. Reasons for discontinuation methotrexate (MTX)
treatment
Reasons to stop MTX therapy n ¼ 65 (%)
Persisting abnormal liver function tests 13 (20)
Dissatisfying results on MTX therapy 9 (14)
Strongly improved skin 9 (14)
Subjective side-effects 7 (11)
Histological abnormalities 6 (9)
Others 21 (32)
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out the possibility of entry bias, e.g. that physicians
do not consider MTX as a therapeutic option for psori-
atic patients with a history of alcohol (ab)use.
We detected a correlation between grades of histo-
logical change and c-GT. In 40% of patients with
Roenigk >1, c-GT was signiﬁcantly elevated. In con-
trast, ASAT, ALAT, and AP serum concentrations were
not elevated beyond the normal range for any of the
Roenigk grades, which ﬁts with other literature
data.10, 19 One of the clinical consequences is that as a
whole, normal liver enzymes do not exclude progres-
sion of liver injury. Conversely, elevated liver enzymes
do not necessarily correlate with MTX induced hepato-
toxicity. In this respect, liver enzymes serve as a poor
predictor for MTX induced liver injury. One exception
may be c-GT levels, as our data are consistent with
the notion that they may serve as a marker for MTX
hepatotoxicity. Regular PIIINP measurements might be
of additional value in monitoring these patients.11, 12
In our study, patients with advanced MTX-induced
ﬁbrosis and cirrhosis (Roenigk ‡ 3a) ran a benign
course. Liver histology did not deteriorate (and some-
times even improved) under ongoing MTX therapy.
Our relatively large series that documented a large
number of biopsies over a 20-year period conﬁrms
those of two small studies.9, 10
In conclusion, MTX-induced ﬁbrosis occurs in a
minority of patients. Liver histology deterioration is
seen mostly at cumulative MTX dosages between 1500
and 6000 mg, which call for close monitoring at this
stage. Our study conﬁrms that normal liver function
tests do not guarantee normal liver histology. Further-
more, risk factors play an important role in the
development of liver injury and they should be taken
into account before the decision is made to start
MTX. Obese patients with or without DM should be
monitored closely by regular liver biopsies. From
our studies it is difﬁcult to indicate a correct interval,
but it is probably more often than stated in the guide-
lines.
ACKNOWLEDGEMENTS
No external funding was received for this study.
REFERENCES
1 Genestier L, Paillot R, Fournel S, et al.
Immunosuppressive properties of met-
hotrexate: apoptosis and clonal deletion
of activated peripheral T cells. J Clin
Invest 1998; 102: 322–8.
2 Zachariae H. Liver biopsies and methot-
rexate: a time for reconsideration? J
Am Acad Dermatol 2000; 42: 531–4.
3 Nyfors A. Liver biopsies from psoriatics
related to methotrexate therapy. 3.
Findings in post-methotrexate liver
biopsies from 160 psoriatics. Acta
Pathol Microbiol Scand [A] 1977; 85:
511–8.
4 Roenigk HH Jr, Maibach HI, Weinstein
GP. Methotrexate therapy for psoriasis.
Guideline revisions. Arch Dermatol
1973; 108: 35.
5 Zachariae H, Grunnet E, Sogaard H.
Liver biopsy in methotrexate-treated
psoriatics-a re-evaluation. Acta Derm
Venereol 1975; 55: 291–6.
6 Campbell MS, Reddy KR. Review article:
the evolving role of liver biopsy. Ali-
ment Pharmacol Ther 2004; 20: 249–59.
7 Bravo AA, Sheth SG, Chopra S. Liver
biopsy. N Engl J Med 2001; 344: 495–
500.
8 de Man RA, van Buuren HR, Hop WC. A
randomised study on the efﬁcacy and
safety of an automated Tru-Cut needle
for percutaneous liver biopsy. Neth J
Med 2004; 62: 441–5.
9 Boffa MJ, Chalmers RJ, Haboubi NY,
et al. Sequential liver biopsies during
long-term methotrexate treatment for
psoriasis: a reappraisal. Br J Dermatol
1995; 133: 774–8.
10 Aithal GP, Haugk B, Das S, et al. Monit-
oring methotrexate-induced hepatic
ﬁbrosis in patients with psoriasis: are
serial liver biopsies justiﬁed? Aliment
Pharmacol Ther 2004; 19: 391–9.
11 Chalmers RJ, Kirby B, Smith A, et al.
Replacement of routine liver biopsy by
procollagen III aminopeptide for monit-
oring patients with psoriasis receiving
long-term methotrexate: a multicentre
audit and health economic analysis. Br
J Dermatol 2005; 152: 444–50.
12 Maurice PD, Maddox AJ, Green CA,
et al. Monitoring patients on methotrex-
ate: hepatic ﬁbrosis not seen in patients
with normal serum assays of aminoter-
minal peptide of type III procollagen. Br
J Dermatol 2005; 152: 451–8.
13 Houtman PM. The practice guideline
‘Photo(chemo)therapy and systemic ther-
apy in severe chronic plaque-psoriasis’.
Ned Tijdschr Geneeskd 2005; 149: 54.
14 Roenigk HH Jr, Auerbach R, Maibach H,
et al. Methotrexate in psoriasis: consen-
sus conference. J Am Acad Dermatol
1998; 38: 478–85.
15 Borchers AT, Keen CL, Cheema GS,
et al. The use of methotrexate in rheu-
matoid arthritis. Semin Arthritis Rheum
2004; 34: 465–83.
16 Haustein UF, Rytter M. Methotrexate in
psoriasis: 26 years’ experience with low-
dose long-term treatment. J Eur Acad
Dermatol Venereol 2000; 14: 382–8.
17 Jansen PL. Nonalcoholic steatohepatitis.
Neth J Med 2004; 62: 217–24.
18 Langman G, Hall PM, Todd G. Role of
non-alcoholic steatohepatitis in methot-
rexate-induced liver injury. J Gastroen-
terol Hepatol 2001; 16: 1395–401.
19 Ahern MJ, Smith MD, Roberts-Thomson
PJ. Methotrexate hepatotoxicity: what is
the evidence? Inﬂamm Res 1998; 47:
148–51.
L IVER INJURY IN LONG-TERM METHOTREXATE TREATMENT FOR PSORIASIS 811
ª 2006 The Authors, Aliment Pharmacol Ther 24, 805–811
Journal compilation ª 2006 Blackwell Publishing Ltd
Chapter 3 - How to improve monitoring of liver toxicity in patients treated with methotrexate
62
Chapter 3 - How to improve monitoring of liver toxicity in patients treated with methotrexate
63
CL IN ICAL STUDIES
Biochemical and biophysical assessmentofMTX-induced liver
¢brosis in psoriasis patients: Fibrotest predicts thepresenceand
Fibroscans predicts theabsenceof signi¢cant liver¢brosis
Maartje A. M. Berends1, Josje Snoek2, Elke M.G.J. de Jong1, J. Han Van Krieken3, Robert J. de Knegt4,
Martijn G. H. van Oijen2, Peter C. M. van de Kerkhof1 and Joost. P. H. Drenth2
1 Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
2 Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
3 Department of Gastroenterology and Hepatology and Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
4 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, the Netherlands
Keywords
liver ﬁbrosis and non-invasive methods –
methotrexate – psoriasis
Correspondence
Maartje A. M. Berends, Department of
Dermatology; Radboud University Medical
Centre Nijmegen, PO Box 9101, 6525 GL
Nijmegen, the Netherlands
Tel: 131 24 3610265
Fax: 131 24 3541184
e-mail: m.berends@derma.umcn.nl
Received 26 September 2006
accepted 22 January 2007
DOI:10.1111/j.1478-3231.2007.01489.x
Abstract
Background: Methotrexate (MTX) use is associated with hepatic ﬁbrosis in
psoriasis patients. To monitor this serial liver biopsies were performed. The
Fibroscans and the Fibrotest are two novel, non-invasive methods that might be
able to assess MTX-induced hepatic ﬁbrosis. Aim: Evaluating the accuracy and
feasibility of the Fibroscans and Fibrotest to detect signiﬁcant MTX-induced liver
ﬁbrosis in psoriasis patients.Methods: We assessed 24 psoriasis patients who had a
recent liver biopsy during MTX use. The results from the Fibroscans and Fibrotest
were compared with liver histology. Results: Fibroscans values (n= 20) ranged
between 3.3 and 18.4 kPa (median value 6.4 kPa) and correctly identiﬁed 88% of
the patients without signiﬁcant liver ﬁbrosis (Metavir score o F2, Fibroscans
� 7.1 kPa). The Fibrotest identiﬁed 83% of the patients with signiﬁcant liver
ﬁbrosis (Metavir score ZF2, Fibrotest >0.31). Conclusion: In this population,
Fibrotest accurately predicted the presence of signiﬁcant liver ﬁbrosis while the
Fibroscans accurately predicted the absence of signiﬁcant liver ﬁbrosis in MTX
users. This suggests that a combination of Fibrotest and Fibroscans should
prospectively be evaluated in monitoring and detecting signiﬁcant MTX-induced
liver ﬁbrosis in psoriasis patients.
Methotrexate (MTX) is the most commonly pre-
scribed systemic drug for severe psoriasis. There is
substantial evidence to suggest that it acts by inhibit-
ing DNA synthesis. Probably as a consequence, it
possesses potent anti-inﬂammatory effects on T-cell
mediated immune responses as it inhibits proliferation
or induces apoptosis in activated T-cells and blocks
abnormal rapid epidermal cell proliferation, both
responsible for the characteristic skin lesions in psor-
iasis (1). Low-dose treatment with MTX is regarded as
an effective therapy for psoriasis.
However, one of the dreaded long-term side effects
includes liver ﬁbrosis and cirrhosis because of MTX
hepatotoxicity. Therefore, frequent evaluation of liver
enzymes and periodic liver biopsy are recommended
during therapy. Speciﬁcally, dermatologic guidelines
call for a liver biopsy at every 1500mg cumulative dose
(2). Although liver biopsy is considered as the golden
standard for the assessment of histological changes
(3), complications such as postprocedural pain and
bleeding limit its clinical use, with a 0.01–0.1% risk of
mortality (4).
Therefore, there is a pressing need for alternative, non-
invasive and reliable methods to monitor MTX-induced
liver injury in psoriasis patients. Non-invasive tools like
blood tests and Fibroscans are being used in patients
with chronic liver diseases (5). This study evaluates two
non-invasive methods for detection of signiﬁcant liver
ﬁbrosis in MTX-treated psoriasis patients.
The ﬁrst test is a recently developed patented artiﬁcial
intelligence algorithm (Fibrotest) that has been vali-
dated to detect ﬁbrosis in hepatitis C patients (6). It is a
biochemical ﬁbrosis index that needs input values of
ﬁve serum markers and is corrected for age and sex,
leading to a composite value (between 0 and 1) to
determine the presence of signiﬁcant liver ﬁbrosis (7, 8).
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As a second test, we measured liver elasticity, using
one-dimensional transient elastography, the Fibroscans.
As liver stiffness roughly correlates with the degree
of hepatic ﬁbrosis, it can serve as a non-invasive
test for ﬁbrosis. This latter approach seems promising
for the assessment of ﬁbrosis and cirrhosis in patients
with hepatitis C and a ﬁne correlation has been
established between signiﬁcant ﬁbrosis (F2 according
to the Metavir histology grade) and elastography
(Fibroscans) outcome (7–10).
We compared the test characteristics of Fibrotest
and Fibroscans in a cohort of psoriasis patients
treated with MTX and compared the results with the
histology of the liver. Our ultimate aim was to identify
effective test alternatives for a liver biopsy.
Patients and methods
Patients
Our study population was drawn from 60 psoriasis
patients who were on MTX treatment at the end of
2005. Patients who underwent a percutaneous liver
biopsy within 18 months of Fibrotest (Biopredictive,
Paris, France) and Fibroscans (Echosens, Paris,
France), as part of their regular MTX monitoring
procedure, were eligible for inclusion in this study.
We contacted 34 patients and asked them to partici-
pate in the study. Twenty-four patients agreed to
participate and gave their written informed consent.
We collected information about the risk factors for
liver damage such as excessive alcohol consumption,
obesity, diabetes mellitus and chronic viral hepatitis
using a structured interview.
Histological assessment
Liver biopsies for histological evaluation of MTX
effects were obtained using a 1.6mm diameter Men-
ghini-type needle via the right intercostal approach
with local lidocaine anaesthesia (Hepaﬁx, Braun, Mel-
sungen, Germany). The biopsy site was marked by
ultrasound examination. There were no complica-
tions. Biopsy specimens were ﬁxed in 4% formalde-
hyde and subsequently embedded in parafﬁn.
Haematoxylin and eosin-stained sections of liver tissue
were examined for steatosis, lobular and portal tract
inﬂammation, hepatocyte necrosis and nuclear varia-
bility. A von Gieson stain for collagen was assessed for
the presence of pericellular and perivenular ﬁbrosis, as
well as the expansion of the portal tracts. All biopsies
were revised and analysed by two independent inves-
tigators (M. A. M. B and J. S.) and veriﬁed by an
experienced pathologist (J. H. v. K.). Disagreements
were resolved by consensus. All liver biopsy specimens
were scored according to the Metavir histology score
(11). Furthermore, the number of portal tracts were
noted and all liver biopsies (previously taken liver
biopsies included), as well as their results (Metavir
score) were reported. A consistent result was deﬁned as
a Roenigk score that was stable over time or increased
gradually. An inconsistent result was deﬁned as a
decrease of more than two grades or a random pattern
with an increase and later a decrease with one grade on
Roenigk classiﬁcation.
Non-invasive measurements of ﬁbrosis
Fibrotest
Blood samples were collected to analyse ﬁve serum
markers included in the Fibrotest score. For this
purpose, we measured the following biological para-
meters: g-glutamyl-transpeptidase (g-GT), total bilir-
ubin level, a2-macroglobulin, apolipoprotein A1
and haptoglobin. In addition, we measured albumine,
alkaline phosphatase, alanine aminotransferase, aspar-
tate aminotransferase and bilirubine.
Measurements were performed immediately on
fresh obtained samples using validated methods. The
results were used as input for the Fibrotest. This is a
patented artiﬁcial intelligence algorithm that generates
a measure of liver ﬁbrosis. It provides a numeric
quantitative estimate of liver ﬁbrosis ranging from
0.00 to 1.00. It is a continuous linear biochemical
assessment of ﬁbrosis stage, which corresponds with
the stages F0–F4 of the Metavir scoring system. Based
on the literature data, we chose a cut-off value of 0.31
to identify patients with signiﬁcant ﬁbrosis (ZF2) (8,
12, 13). Fibrotest results were kindly provided by
T. Poynard, University Paris VI, Paris, France (www.
biopredictive.com).
Fibroscans
We performed the Fibroscans measurements on the
same day as the measurements of the biological para-
meters that are used for the Fibrotest. The Fibroscans
is an ultrasound transducer that generates vibrations
that cause a slow elastic shear wave. The propagation
and velocity of the wave in the liver are tracked by
pulse-echo ultrasound and correlate to tissue stiffness.
Measurements were performed on the right lobe of the
liver, at the same target area for liver biopsy. The
procedure was performed through the intercostal
space while the patients were lying on their backs with
their arms in maximal abduction behind their heads.
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Each patient underwent a series of 10 validated
electrographic measures. The success rate was calcu-
lated as the number of validated measurements di-
vided by the total number of measurements. The
results were expressed in kilopascals (kPa) and accord-
ing to Castera a cut-off value of 7.1 kPa was chosen to
identify patients with signiﬁcant ﬁbrosis (ZF2) (7).
The median value was considered to be representative
for the elasticity of the liver. Only procedures with 10
validated measurements and a success rate of at least
60% were considered to be reliable. Fibroscans assess-
ments were performed by an experienced physician
(R. J. d. K.) who was strictly blinded to the histological
outcome.
Cumulative MTX dose and the three tests
We next went on to test the effect of cumulative MTX
usage on the presence of liver ﬁbrosis as assessed by the
three tests under study. The presence of liver ﬁbrosis
was deﬁned as the presence of MetavirZF2 on a liver
biopsy specimen.
Statistical analysis
Frequency tables were provided for both demographic
and clinical information (cumulative MTX dose, alco-
hol consumption and the presence of diabetes melli-
tus). The diagnostic performance of the non-invasive
methods for liver ﬁbrosis was measured as sensitivity,
speciﬁcity, positive predictive value, negative predic-
tive value and accuracy for the presence and absence of
signiﬁcant ﬁbrosis (>F2). The results of both tests were
drawn in a scatterplot with regression lines of indivi-
dual Metavir scores in relationship with the results of
Fibrotest and Fibroscans. Furthermore, we compared
the two non-invasive tests using the non-parametric
Spearman correlation test, both continuously and
subdivided for Metavir score. Finally, the relation
between the cumulative MTX dose and the results of
the three tests was tested with the Wilcoxon’s rank sum
analysis. All statistical analyses were undertaken with
SAS statistical software (SAS institute, Minneapolis,
MN, USA), version 8.2.
Results
Demographics
We included 24 psoriasis patients (13 females, 11
males) with a mean age of 55 years (range 34–73).
The reasons for performing a liver biopsy were as
follows: all patients underwent a liver biopsy in keep-
ing with the guideline after a median dosage of
1635mg MTX (range 162–2354mg). Only one patient
had elevated liver enzymes more than twice the upper
limit. Sixteen patients were biopsied before.
The median body mass index was 26 kg/m2 (range
20–38 kg/m2) and 14 patients were considered to be
overweight (deﬁned as body mass index >25 kg/m2).
Ten patients consumed alcohol, while a single patient
was an excessive consumer (>14U/week) and four
patients had diabetes mellitus. Patients received a
median cumulative MTX dose of 3352mg
(314–20 235) during a median follow-up period of
346 weeks (111–2162). Four patients had a cumulative
dose of more than 5000 g. Table 1 shows the main
demographic and clinical features of the population
studied.
Histology
In the population studied, the median biopsy length
was 30mm (range 10–60mm). Five patients (21%)
had a liver biopsy specimen shorter than 15mm. The
mean number of portal tracts was 22 (SD 9). Scoring
with the Metavir classiﬁcation resulted in ﬁve patients
with a liver biopsy classiﬁed as F0, 13 as F1, 4 as F2, 1
as F3 and 1 as F4.
Sixteen patients had more than one liver biopsy.
Thirteen patients (81%) had consistent pathological
scoring of their liver biopsies over the years. In only
three patients the histology results varied between
biopsies (Table 2).
In patient 3, the time period between the ﬁrst two
biopsies was 6 months. Treatment with MTX was
discontinued then, but was restarted 14 years later.
Histology of the follow-up biopsy 18 months later
Table 1. Main demographic and clinical features of the studied
population
N=24
Male gender (%) 11 (46)
Median age, years (range) 55 (34–73)
Median body mass index, kg/m2 (range) 26 (20–38)
Diabetes mellitus (%) 4 (17)
Median cum dose MTX, mg (range) 3352 (314–20 235)
Median Fibroscan, kPa (range) 6.4 (3.3–18.4)
Median Fibrotest (range) 0.32 (0.06–0.93)
MTX, methotrexate.
Table 2. Three patients with inconsistent histology
Patients Histology according to Roenigk score
1 R1 R3a R1 R3a R2
2 R1 R3a R1 R1
3 R1 R1 R3a R2 R1
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resulted in an R1. In patient 2, the time period
between the second and third biopsy was half a year.
The last two biopsies were consistent and the time
period between them was 3 years. In patient 1, time
periods between biopsies were 3 years, 8 months, 4.5
years and 10 months. The median length of the
consistent biopsies was 25mm (8–85mm) vs a median
length of 24.5mm (9–45mm) of the inconsistent
biopsies.
Fibrotest
Fibrotest values (n= 24) ranged between 0.06 and 0.93
(median value 0.32). Table 3 shows the diagnostic test
properties for the Fibrotest with respect to detection of
signiﬁcant liver ﬁbrosis (Metavir ﬁbrosis score ZF2).
Figure 1 shows the agreement in Metavir score be-
tween the ﬁbrotest and histology. The results show
that Fibrotest correctly identiﬁes those patients with
signiﬁcant ﬁbrosis in 83% of the cases, indicating good
screening properties (Metavir ﬁbrosis score ZF2,
Fibrotest o 0.31).
Fibroscans
The mean number of measurements per patient was
12.1� 2 (range: 10–18) to obtain 10 evaluable values.
The success rate of liver elastography measurements
was 85� 12%. The total procedure failed in four
(17%) patients because of the presence of obesity.
These patients had a body mass index (BMI) of 35.4,
32.4, 38.2 and 32.7 kg/m2, Metavir histology scores F0,
F1, F3 and F2 and Metavir Fibrotest scores F0, F3, F3
and F4.
Liver stiffness measurements (n= 20) ranged be-
tween 3.3 and 18.4 kPa (median value 6.4 kPa). Table
3 shows the diagnostic test properties for the
Fibroscans in our study population with respect to
detection of signiﬁcant liver ﬁbrosis (Metavir ﬁbrosis
score ZF2). The test detected 88% of the patients
without signiﬁcant ﬁbrosis (Metavir ﬁbrosis score
o F2) in this population, indicating good diagnostic
properties. Figure 1 shows the agreement in Metavir
score between the ﬁbrotest ﬁbroscan and histology.
Relationship cumulative MTX dose results of three
tests
There was no effect of cumulative MTX dosing on the
presence of liver ﬁbrosis. Patients with signiﬁcant liver
ﬁbrosis (Metavir ﬁbrosis score ZF2) did not have a
higher cumulative MTX dose than patients without
signiﬁcant liver ﬁbrosis as assessed by any of the three
tests (Table 4).
Discordance between ﬁbrotest and ﬁbroscans
In nine patients, Fibroscans and Fibrotest resulted in
different Metavir scores with a discordance of two
stages. In four of them, the total Fibroscans procedure
failed because of the presence of obesity. In the
remaining ﬁve, biopsy length was signiﬁcantly shorter
Table 3. Diagnostic value of ﬁbrotest and ﬁbroscan in detecting
patients with clinically signiﬁcant ﬁbrosis (METAVIR ﬁbrosis score
F2 or greater)
Fibrotest
ZF2
Fibroscan
ZF2
Optimal cut-off 0.31 7.1 kPa
Sensitivity (%) 83 50
Speciﬁcity (%) 61 88
Accuracy (%) 67 70
Positive predictive value (%) 42 33
Negative predictive value (%) 92 86
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Fig. 1. Scatterplot representing all observations and regression
lines for both Fibrotest (dashed line) and Fibroscans (regular
line).
Table 4. Relationship cum MTX dose vs test
Median cum dose MTX, mg (range)
P�Metavir o F2 MetavirZF2
Histology 3879 (314–20 235) 2791 (1445–3882) 0.45
Fibroscan 4396 (314–18 502) 4467 (1400–15 173) 0.40
Fibrotest 2166 (314–6000) 4026 (1445–20 235) 0.10
�Tested with the Wilcoxon’s rank-sum test.
MTX, methotrexate.
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compared with the biopsy length of the remaining
patients. There was no signiﬁcant difference in BMI
between those patients. Other potential confounders
for failure of Fibrotest like Gilbert, haemolysis and
acute inﬂammation were ruled out.
Discussion
Our aim was to evaluate the accuracy and feasibility of
two non-invasive methods, Fibrotest and Fibroscans,
in the detection of signiﬁcant MTX-induced liver
ﬁbrosis, using liver biopsy as the gold standard, in a
cohort of psoriasis patients. Speciﬁcally, in our popu-
lation we found that the Fibroscans is a good diag-
nostic test for excluding signiﬁcant liver ﬁbrosis (ZF2
on the Metavir score) but less equipped in detecting
signiﬁcant ﬁbrosis (ZF2) in this population. On the
other hand, we found that the ﬁbrotest is a good
screening test in detecting signiﬁcant ﬁbrosis. This
suggests that a complementary use of both Fibrotest
and Fibroscans is beneﬁcial in establishing the grade
of liver ﬁbrosis in MTX-induced liver ﬁbrosis in
psoriasis patients and might be instrumental in redu-
cing the need for liver biopsies.
The Fibroscans results of this study accord with
those collected from the literature. It had a comparable
accuracy in excluding signiﬁcant liver ﬁbrosis in a
sample of patients with hepatitis C, but also in a series
of patients with Crohn’s disease on MTX treatment
(7, 8, 10, 14, 15).
Our sample contained only a few patients with F3
or F4 liver ﬁbrosis. Thus, we mainly based our con-
clusion on patients with a Metavir histology grade
F0–F2. However, in another study ﬁbroscans was
prospectively investigated in a large cohort of patients
with chronic liver disease of various aetiologies in-
cluding 144 (20%) of patients with F3/F4 ﬁbrosis.
There diagnostic performances forZF2 were compar-
able to our results, sensitivity 50% vs 64% and
speciﬁcity 85% vs 88% (9).
Because continuous long-term use of MTX is asso-
ciated with hepatotoxicity, frequent evaluation of liver
function tests and periodic liver biopsy are recom-
mended during therapy. Speciﬁcally, dermatologic
guidelines call for a liver biopsy at every 1500mg
cumulative dose (2). Conventional liver enzyme tests
(ALT or g-GT) correlate poorly with histological
changes (3). Therefore, liver biopsy is considered as
the gold standard method in the assessment of histo-
logical changes. A recent study by our group about
liver injury in long-term MTX treatment in 125
patients with psoriasis with 278 liver biopsies found
that progression to a higher stage of liver injury mostly
occurred at a cumulative dose range between 1500 and
6000mg, which translates to at least 2 years of MTX
treatment at 15mg weekly. Furthermore, in this study,
ASAT, ALAT and AF serum concentrations were not
elevated beyond the normal range for any of the
Roenigk grades (16).
A liver biopsy has some important limitations. It is
an invasive procedure and carries several known risk
factors such as pain, localized bleeding and less often
pneumothorax, haemothorax, bile peritonitis, haemo-
bilia, and inadvertent puncture of the kidney or
intestine (17, 18). The complication risk of a liver
biopsy is approximately 1–2%, with a 0.01–0.1% risk
of mortality (4). Furthermore, it causes anxiety, which
is an issue, as most psoriasis patients on the MTX
require repeated liver biopsy during the course of their
treatment. Another limitation of the liver biopsy is the
possible sampling error, an intra- and inter- patholo-
gist inconsistency in observations and that there are
discontinuous and hence semi-quantitative histologi-
cal scoring systems (2, 3, 7, 12, 15, 17, 19, 20). In three
patients, histology results varied considerably between
biopsies (inconsistent). In one patient, this might have
been caused by the improvement of liver tissue during
a long period in which the patient had not been treated
with MTX, which favours the hypothesis that MTX-
induced injury is reversible and in another patient the
last two biopsies were consistent. To conclude, only in
one patient histology results might have reﬂected a
sampling error of liver biopsy.
There is an urgent need for alternative, non-invasive
and reliable methods of monitoring and detecting
MTX-induced liver injury in psoriasis patients. Fi-
brotest has been studied in patients with hepatitis B
and C, alcoholic liver disease and in patients with non-
alcoholic fatty liver disease (21–27). Previous studies
found that non-invasive assessment of liver stiffness
by use of the Fibroscans is a reliable test to detect
signiﬁcant ﬁbrosis or cirrhosis (8–10, 14, 15). The
positive predictive value for detecting signiﬁcant
ﬁbrosis is only 76%, but the combined use of
Fibroscans and Fibrotest does allow the evaluation of
hepatitis C liver ﬁbrosis (7, 28). In one study the
stepwise combination of non-invasive markers of liver
ﬁbrosis improved the diagnostic performance in
chronic hepatitis C patients. The need for liver biopsy
in that study was reduced by 50–70% (28).
The main advantage of Fibroscans compared with
the Fibrotest is that it provides a direct quantative
physical parameter. In obese patients, the fatty thor-
acic belt attenuates both elastic waves and ultrasound,
rendering it difﬁcult or even impossible (15). In our
study, 12 patients suffered from obesity and in three of
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them the Fibroscans failed. Psoriasis patients tend to
be more obese compared with the normal population,
with a prevalence of 34% in psoriasis patients vs 18%
in the normal population (29), which might make this
approach less successful in detecting MTX-induced
liver injury in psoriatic patients.
In the search for a non-invasive method to monitor
and detect MTX–induced liver injury, Amino terminal
peptide of type III procollagen (PIIINP) was studied
before (4, 30). PIIINP may serve as an alternative for
routinely performed liver biopsies when measured
levels at regular intervals are consistently normal in
otherwise healthy adults. This is because PIIINP is not
an organ-speciﬁc protein and may be raised in chil-
dren and various pathological states associated with
development of ﬁbrosis including inﬂammatory ar-
thritis, scleroderma, hyperthyroidism, scar formation
following burns and myocardial infarction (4, 30). The
advantage that Fibrotest offers over PIIINP is that one
cross-sectional measurement is sufﬁcient to judge
whether liver ﬁbrosis is present.
A limitation of our study is the relatively small study
population, which may limit the precision of the effect
estimates. Furthermore, as mentioned above, a liver
biopsy, although considered as the gold standard, can
have sampling variability problems. This might have
been the case in our study because some patients had
small liver biopsies. However, in our study liver biopsy
length compares favourably with that of some other
studies (9, 31) and only one patient had a liver biopsy
with less than 10 portal tracts.
The pattern of results indeed supports the notion
that the diagnostic test properties of Fibroscans and
screening properties of Fibrotest should be evaluated
in a prospective manner. Speciﬁcally, we would like to
propose a prospective controlled trial that evaluates
the combined use of non-invasive markers such as the
Fibrotest, Fibrotest and PIIINP in the detection of
MTX-associated ﬁbrosis (7, 28).
Although it should be kept in mind that this is a
small pilot study, based on our results we conclude
that the Fibrotest seems to be good in detecting and the
Fibroscans seems to be good in excluding signiﬁcant
MTX-induced liver ﬁbrosis (FZ2) in patients with
psoriasis treated with MTX. This suggests that the
combined use of Fibrotest and Fibroscans may be
beneﬁcial in establishing the grade of liver ﬁbrosis in
MTX-induced liver ﬁbrosis in psoriasis patients.
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STUDY
Reliability of the Roenigk Classification of Liver
Damage After Methotrexate Treatment for Psoriasis
A Clinicopathologic Study of 160 Liver Biopsy Specimens
Maartje A. M. Berends, MD; Martijn G. H. van Oijen, MSc; Josje Snoek, MSc; Peter C. M. van de Kerkhof, MD, PhD;
Joost P. H. Drenth, MD, PhD; J. Han van Krieken, MD, PhD; Elke M. G. J. de Jong, MD, PhD
Objective: To determine the interobserver reliability
of the Roenigk score as a classification system of liver
damage and its possible consequences for clinical
practice.
Design: Retrospective study.
Setting: Academic research.
Patients:Onehundred sixty liver biopsy specimens from
patients with psoriasis receiving methotrexate treat-
ment were rereviewed and analyzed blindly by an expe-
rienced pathologist with an interest in liver pathologic
conditions.
Main OutcomeMeasure: Interobserver variation was
evaluated using � statistics.
Results: A high concordance was present in the evalu-
ation of the Roenigk grade of fibrosis (weighted �=0.73;
95% confidence interval, 0.63-0.83). Agreementwas good
regarding the number of biopsy specimens for patients
whose clinical management should be changed (�=0.71;
95% confidence interval, 0.56-0.87).
Conclusion: The Roenigk classification in the assess-
ment of liver fibrosis is a reliable scoring system.
Arch Dermatol. 2007;143(12):1515-1519
H EPATIC FIBROSIS AND CIR-rhosis represent a conse-quence of methotrexatetreatment in patientswithpsoriasis.1-6 Therefore, the
assessment of liver damage is essential in
the clinical management of these pa-
tients. Sequential liver biopsies followed
by Roenigk grading by a pathologist are
themainstay in the assessment of the stage
and degree of liver damage.7-9 Unfortu-
nately, liver biopsies may be associated
with sampling error, potential complica-
tions, and interobserver variability.1,7,9-13
Methotrexate-associated liver damage
in patients with psoriasis is graded accord-
ing to the Roenigk classification.1 The re-
sults of the Roenigk scoring system should
be reproducible, with little interobserver
error.
The Roenigk classification was devel-
oped by the Psoriasis Task Force (led by
dermatologists), is based on clinical ob-
servations, and has been recommended in
the American Academy of Dermatology
guidelines for monitoring methotrexate-
induced liver injury.1,9,14 However, the
Roenigk grading system is subjective, in-
cluding some features (such as nuclear
pleomorphism) of unclear significance,
and is insensitive to small changes, par-
ticularly when assessing fibrosis.1,15,16 Al-
though scoring seems to consider changes
such as steatosis and inflammation, their
presence or absence has no weight in the
allocation to more advanced grades. The
system categorizes all biopsy specimens
with more than minimal fibrosis as ad-
vanced fibrosis (Roenigk grade 3b) and
overestimates the degree of histologic
change. Accurate assessment is essential
because misclassification of pathologic
changes affects clinical management. For
example, if the degree of fibrosis is up-
graded from none (Roenigk grade 2) to
mild (Roenigk grade 3a), guidelines call
for a second liver biopsy within 6months
instead of a 1.5-g cumulative dose of
methotrexate.9 In the case of Roenigk grade
3b or 4, the guidelines recommend dis-
continuation of therapy.
In some European countries, the num-
ber of liver biopsies has declined for sev-
eral reasons. The use of the aminotermi-
nal propeptide of type III procollagen
(PIIINP) has reduced the number of liver
biopsies in Scandinavia and in Great Brit-
ain. Until recently, no noninvasivemethod
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has been available that could completely replace the liver
biopsy. In the case of a persistently elevated PIIINP, liver
biopsy is still advised.11,13,17 Given the critical nature of
this tool, we evaluated interobserver variation using a
sample of 160 liver biopsy specimens frommethotrexate-
treated patients with psoriasis.
METHODS
PATIENTS
We evaluated interobserver variation between several differ-
ent pathologists with an interest in liver pathologic routine clini-
cal practice and 1 of us (J.H.v.K.) in the assessment of the his-
topathologic degree of liver damage according to the Roenigk
scale in patients with psoriasis receiving methotrexate treat-
ment. All pathologists were trained at the same department of
pathology at the same hospital.
One hundred twenty-five patients with psoriasis had un-
dergone 278 liver biopsies while receiving methotrexate treat-
ment from November 1, 1976, to December 31, 2005. We ex-
cluded biopsies performed before December 31, 1995, because
these specimens were unavailable for review. In addition, 9 bi-
opsy specimens were excluded from analysis (6 because they
were unavailable from the department’s archives, 1was too small
to evaluate the degree of fibrosis, and 2 because the vanGieson–
stained slide was unavailable). One hundred sixty liver biopsy
specimens from 95 patients were reexamined independently
by 1 of us (J.H.v.K.) who was blinded to the clinical details of
the patients. Liver biopsy specimens were graded according to
the Roenigk classification (Table 1).1
HISTOLOGIC EXAMINATION
Percutaneous liver biopsy was performed via a right intercos-
tal approach using local lidocaine hydrochloride anesthesia. The
biopsy specimen was immersed in 2% formaldehyde and was
subsequently fixed with paraffin. Hematoxylin-eosin–stained
sections of liver tissuewere examined for steatosis, nuclear vari-
ability, hepatocyte necrosis, and lobular and portal tract in-
flammation. A van Gieson stain for collagen was used to as-
sess for the expansion of the portal tracts and for the presence
of pericellular and perivenular fibrosis.
PATHOLOGIC EXAMINATION
All liver biopsy specimens, sampled as part of the monitoring
process of methotrexate-induced hepatic injury, were graded
according to the Roenigk classification. A description of the
Roenigk classification is given in Table 1. Roenigk grade 1 in-
dicates normal tissue with no fibrosis, no or mild portal in-
flammation, and no or mild fatty changes and nuclear pleo-
morphism.Grade 2 indicates no fibrosis andmoderate or severe
fatty changes, nuclear pleomorphism, and portal inflamma-
tion. Grade 3a indicates mild fibrosis, portal fibrotic septa, ex-
tension into the lobuli, and portal tract enlargement. Grade 3b
indicates moderate or severe fibrosis. Grade 4 indicates cirrho-
sis, regenerating noduli, and bridging of the portal tracts.
STATISTICAL ANALYSIS
To judge the degree of interobserver agreement, we calculated
weighted � statistics for the 5-point Roenigk scale. For analy-
sis of clinical consequences, we dichotomized the Roenigk score
into “no changes of treatment necessary” (Roenigk grades 1 and
2) and “change of treatment necessary” (Roenigk grades 3a, 3b,
and 4) for all observations. For agreement of the dichoto-
mized data, we again used � statistics. Interpretation of the �
statistics was performed using the scale described by Landis and
Koch,18 in which � statistics less than 0.4 indicate poor agree-
ment, � statistics between 0.4 and 0.6 indicate moderate agree-
ment, between 0.6 and 0.8 good agreement, and greater than
0.8 indicate excellent agreement.19
To visualize agreement, we plotted a Bland-Altman curve
for the 5-point Roenigk score. Using a 2-sided t test, we tested
whether the overall mean differences differed statistically sig-
nificantly from 0. All analyses were undertaken using statisti-
cal software (SAS version 8.2; SAS Institute Inc, Cary, North
Carolina).
RESULTS
DEMOGRAPHICS
Ninety-five patientswith psoriasis (44 female and51male)
underwent a liver biopsy between December 31, 1995,
andDecember 31, 2005. Themaximumprescribedweekly
dosage of methotrexate was 12.5 mg (range, 7.5-25mg).
Patients received amedian cumulativemethotrexate dose
of 2051mg (range, 119-20 235mg) during amedian fol-
low-up period of 202 weeks (range, 20-1763 weeks).
LIVER BIOPSY SPECIMENS
The concordance between the Roenigk grades as scored
during routine assessment and at subsequent scoring by
the second pathologist was high (weighted �=0.73;
95% confidence interval, 0.63-0.83). The agreement
was higher for biopsy specimens that were graded as
Roenigk grade 1, which was the most common Roenigk
score (Figure). The mean difference was 0.03 and did
not significantly differ from 0 (P� .05). Among liver bi-
opsy specimens that resulted in a change of clinical
management (Roenigk grades 3a, 3b, and 4), we like-
Table 1. Roenigk Classification System
Fatty Change Nuclear Pleomorphism Fibrosis Necroinflammation Roenigk Gradea
Mild or none Mild or none None With or without mild portal inflammation 1
Moderate or severe Moderate or severe None Moderate or severe portal inflammation 2
With or without With or without Mild (fibrosis extending into acini) With or without 3a
With or without With or without Moderate or severe With or without 3b
With or without With or without Cirrhosis With or without 4
aSee the “Pathologic Examination” subsection of the “Methods” section for an explanation of Roenigk grades.
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has been available that could completely replace the liver
biopsy. In the case of a persistently elevated PIIINP, liver
biopsy is still advised.11,13,17 Given the critical nature of
this tool, we evaluated interobserver variation using a
sample of 160 liver biopsy specimens frommethotrexate-
treated patients with psoriasis.
METHODS
PATIENTS
We evaluated interobserver variation between several differ-
ent pathologists with an interest in liver pathologic routine clini-
cal practice and 1 of us (J.H.v.K.) in the assessment of the his-
topathologic degree of liver damage according to the Roenigk
scale in patients with psoriasis receiving methotrexate treat-
ment. All pathologists were trained at the same department of
pathology at the same hospital.
One hundred twenty-five patients with psoriasis had un-
dergone 278 liver biopsies while receiving methotrexate treat-
ment from November 1, 1976, to December 31, 2005. We ex-
cluded biopsies performed before December 31, 1995, because
these specimens were unavailable for review. In addition, 9 bi-
opsy specimens were excluded from analysis (6 because they
were unavailable from the department’s archives, 1was too small
to evaluate the degree of fibrosis, and 2 because the vanGieson–
stained slide was unavailable). One hundred sixty liver biopsy
specimens from 95 patients were reexamined independently
by 1 of us (J.H.v.K.) who was blinded to the clinical details of
the patients. Liver biopsy specimens were graded according to
the Roenigk classification (Table 1).1
HISTOLOGIC EXAMINATION
Percutaneous liver biopsy was performed via a right intercos-
tal approach using local lidocaine hydrochloride anesthesia. The
biopsy specimen was immersed in 2% formaldehyde and was
subsequently fixed with paraffin. Hematoxylin-eosin–stained
sections of liver tissuewere examined for steatosis, nuclear vari-
ability, hepatocyte necrosis, and lobular and portal tract in-
flammation. A van Gieson stain for collagen was used to as-
sess for the expansion of the portal tracts and for the presence
of pericellular and perivenular fibrosis.
PATHOLOGIC EXAMINATION
All liver biopsy specimens, sampled as part of the monitoring
process of methotrexate-induced hepatic injury, were graded
according to the Roenigk classification. A description of the
Roenigk classification is given in Table 1. Roenigk grade 1 in-
dicates normal tissue with no fibrosis, no or mild portal in-
flammation, and no or mild fatty changes and nuclear pleo-
morphism.Grade 2 indicates no fibrosis andmoderate or severe
fatty changes, nuclear pleomorphism, and portal inflamma-
tion. Grade 3a indicates mild fibrosis, portal fibrotic septa, ex-
tension into the lobuli, and portal tract enlargement. Grade 3b
indicates moderate or severe fibrosis. Grade 4 indicates cirrho-
sis, regenerating noduli, and bridging of the portal tracts.
STATISTICAL ANALYSIS
To judge the degree of interobserver agreement, we calculated
weighted � statistics for the 5-point Roenigk scale. For analy-
sis of clinical consequences, we dichotomized the Roenigk score
into “no changes of treatment necessary” (Roenigk grades 1 and
2) and “change of treatment necessary” (Roenigk grades 3a, 3b,
and 4) for all observations. For agreement of the dichoto-
mized data, we again used � statistics. Interpretation of the �
statistics was performed using the scale described by Landis and
Koch,18 in which � statistics less than 0.4 indicate poor agree-
ment, � statistics between 0.4 and 0.6 indicate moderate agree-
ment, between 0.6 and 0.8 good agreement, and greater than
0.8 indicate excellent agreement.19
To visualize agreement, we plotted a Bland-Altman curve
for the 5-point Roenigk score. Using a 2-sided t test, we tested
whether the overall mean differences differed statistically sig-
nificantly from 0. All analyses were undertaken using statisti-
cal software (SAS version 8.2; SAS Institute Inc, Cary, North
Carolina).
RESULTS
DEMOGRAPHICS
Ninety-five patientswith psoriasis (44 female and51male)
underwent a liver biopsy between December 31, 1995,
andDecember 31, 2005. Themaximumprescribedweekly
dosage of methotrexate was 12.5 mg (range, 7.5-25mg).
Patients received amedian cumulativemethotrexate dose
of 2051mg (range, 119-20 235mg) during amedian fol-
low-up period of 202 weeks (range, 20-1763 weeks).
LIVER BIOPSY SPECIMENS
The concordance between the Roenigk grades as scored
during routine assessment and at subsequent scoring by
the second pathologist was high (weighted �=0.73;
95% confidence interval, 0.63-0.83). The agreement
was higher for biopsy specimens that were graded as
Roenigk grade 1, which was the most common Roenigk
score (Figure). The mean difference was 0.03 and did
not significantly differ from 0 (P� .05). Among liver bi-
opsy specimens that resulted in a change of clinical
management (Roenigk grades 3a, 3b, and 4), we like-
Table 1. Roenigk Classification System
Fatty Change Nuclear Pleomorphism Fibrosis Necroinflammation Roenigk Gradea
Mild or none Mild or none None With or without mild portal inflammation 1
Moderate or severe Moderate or severe None Moderate or severe portal inflammation 2
With or without With or without Mild (fibrosis extending into acini) With or without 3a
With or without With or without Moderate or severe With or without 3b
With or without With or without Cirrhosis With or without 4
aSee the “Pathologic Examination” subsection of the “Methods” section for an explanation of Roenigk grades.
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wise observed a good correlation (�=0.71; 95% confi-
dence interval, 0.56-0.87).
The initial routine examination had graded 113 liver
biopsy specimens as Roenigk grade 1, 21 as grade 2, 22
as grade 3a, 3 as grade 3b, and 1 as grade 4 (Table 2).
After reexamination of all liver biopsy specimens by the
second pathologist, 118 were graded as grade 1, 18 as
grade 2, 18 as grade 3a, 4 as grade 3b, and 2 as grade 4.
Six liver biopsy specimens originally scored as Roenigk
grade 1 were scored differently by the second patholo-
gist (3 as grade 2 and 3 as grade 3a). Ten liver biopsy
specimens originally scored as grade 2 were subse-
quently scored differently (2 were upgraded to grade 3a,
while 8 were downgraded to grade 1). Nine liver biopsy
specimens originally scored as grade 3a were scored dif-
ferently by the second pathologist (2 as grade 3b, 4 as
grade 2, and 3 as grade 1). Finally, 1 liver biopsy speci-
men originally scored as grade 3b was subsequently up-
staged to grade 4.
CLINICAL CONSEQUENCES
OF DIFFERENCES IN SCORING
Fourteen biopsy specimens were downgraded or up-
graded to such an extent that it would have affected clini-
cal management (Table 3). Seven biopsy specimens
graded as Roenigk grade 3a were downgraded by the sec-
ond pathologist to grade 2 or 1. Because of the original
grade, follow-up biopsies in 3 patients were performed
after 5 to 10 months, and methotrexate treatment in
1 patient was discontinued after 5 months. Three bi-
opsy specimens were upgraded by the second patholo-
gist from grade 1 to 3a, 2 biopsy specimens from grade 2
to 3a, and 2 biopsy specimens from grade 3a to 3b. In
the latter 2 cases, this assessment resulted in follow-up
biopsies after 9 and 14 months that demonstrated his-
tologic findings corresponding to grade 3a. One of these
patients is still being treated with methotrexate. In the
other patient,methotrexate treatmentwas continued, and
2 more biopsies were performed. Both biopsy speci-
mens demonstrated histologic findings corresponding to
grade 3a. Methotrexate treatment was discontinued for
an unknown reason.
COMMENT
Our objectives were to determine the interobserver re-
liability of the Roenigk score as a classification system
of methotrexate-induced liver damage and to assess the
consequences for clinical practice. The results of this study
show that the Roenigk classification is a reliable scoring
system for the assessment of liver fibrosis.
The study revealed high concordance between the first
and second observations. Also, there was good agree-
ment onbiopsy specimens that resulted in aRoenigk grade
that necessitated change of clinical management (bi-
opsy specimenswith grades 3a, 3b, and 4). Although only
a small percentage of the biopsy specimens was scored
differently by the second pathologist, it would have re-
sulted in a clear change in the clinical decisions made.
Grade 3a requires more frequently performed liver bi-
opsies (within 6 months instead of a 1.5-g cumulative
dose of methotrexate), and grades 3b and 4 necessitate
interruption and cessation of methotrexate treatment.9
Periodic liver biopsies are recommended by interna-
tional guidelines4,9,14 on methotrexate treatment in pa-
tients with psoriasis, and the Roenigk score has been rec-
ommended in the American Academy of Dermatology
guidelines4,9,14 to classifymethotrexate-induced liver dam-
age. However, the Roenigk scale has not been validated
or used (to our knowledge) in the evaluation of any other
liver disease.1 Furthermore, the Roenigk scale is subjec-
tive and is insensitive to small changes, particularly when
assessing fibrosis.1,16 Scoring systems for liver damage such
as theMetavir, Scheuer, and Ishak classifications are well
established for hepatitis C and for some forms of nonvi-
ral hepatitis; these scoring systems are more sensitive to
small changes, and studies1,20-24 demonstrated good agree-
ment for fibrosis assessment. As far as we know, there
are no studies evaluating the validity and interobserver
reliability of the Roenigk score. However, 2 studies com-
pare the Roenigk classification with other scoring sys-
tems. One study15 compares the Roenigk score with a
Table 2. Numbers of Slides Assigned to the Roenigk Grades
by the Pathologistsa
Roenigk Grade First Pathologist Second Pathologist
1 113 118
2 21 18
3a 22 18
3b 3 4
4 1 2
aSee the “Pathologic Examination” subsection of the “Methods” section
for an explanation of Roenigk grades.
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Figure. Bland-Altman curve. The graph shows the absolute difference
between the initial and subsequent scores (on the y-axis) against the mean
of both scores (on the x-axis) for each observation. In the graph, the size of
the crosses indicates how often a pair of observations is found. The red line
indicates the 0.03 overall mean difference between the initial and subsequent
scores.
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semiquantitative histologic scoring system for the evalu-
ation of hepatic fibrosis in patients with rheumatoid ar-
thritis treated with methotrexate. A statistically signifi-
cant correlation was found between the 2 classification
systems, but the semiquantitative histologic scoring sys-
temwasmuchmore sensitive than the Roenigk score for
the assessment of hepatic fibrosis. Another study1 com-
pared 3 scoring systems for the evaluation of hepatic fi-
brosis in patients with psoriasis treated with methotrex-
ate. The Roenigk classification was compared with the
Scheuer and Ishak scoring systems and seemed to cor-
relate poorly with both systems.
The already described simplification of the Roenigk
classification may have improved the interobserver reli-
ability in our study. This raises the question of whether
the Roenigk classification is the best-designed scoring sys-
tem to classify methotrexate-induced liver injury. How-
ever, that was not the objective of our study. The Roenigk
classification is used by many pathologists to classify
methotrexate-induced liver fibrosis. In this study, it is
shown that the interobserver reliability is good.
In 8% of the liver biopsy specimens, a different clini-
cal decision would have been made based on disagree-
ment between the first and second observers. When this
leads to more frequently performed liver biopsies, seri-
ous consequences arise for the patient. Patients will be
at greater risk formorbidity andmortality associatedwith
liver biopsies such as postprocedural pain, bleeding, and
(less often) pneumothorax. Also, an increase in liver bi-
opsies has socioeconomic consequences such as ab-
sence from work. Unnecessary liver biopsies should be
avoided, and there is a need for alternative noninvasive
and reliable methods to monitor methotrexate-induced
liver injury in patients with psoriasis. Several noninva-
sive methods have been tested as a screening for liver fi-
brosis and liver cirrhosis (eg, the Fibrotest, Fibroscan,
and PIIINP).11,13,17,25 Another serious consequence would
be the risk of missed pathologic findings that would ne-
cessitate discontinuing methotrexate treatment or un-
dergoing another liver biopsy in 6 months.
This study was composed of a rereview of 160 liver
biopsy specimens by 1 of us (J.H.v.K.). However, the ret-
rospective nature of the study has some limitations, which
might be reflected in the differences in the results found.
Slides could have lost some of their stains, and observa-
tion of slides serially (by the second pathologist) or in-
dividually (by the first pathologist) could have resulted
in some of the differences.
One biopsy specimen was excluded from the study be-
cause it was too small to evaluate the degree of fibrosis. A
hepatologist experienced in performing liver biopsies and
in repeating liver biopsy procedures is essential for obtain-
ing adequate specimens and for the safety of the patient.
Based on this study, we conclude that the interob-
server reliability of the Roenigk classification is good and
that it can be used as a scoring system for methotrexate-
induced liver damage. However, the clinical conse-
quences of rereviewwere substantial. Experiencedpatholo-
gists with an interest in liver pathologic conditions are
recommended, aswell asparticular attention tobiopsy speci-
mens with Roenigk grades 3a and 3b. The search for non-
invasive alternatives to liver biopsy should be continued.
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Chapter 4 is about the management, safety and efﬁcacy of the treat-
ment of patients with moderate to severe psoriasis with etanercept 
and efalizumab. 
Many patients are challenged to manage their disease for decades. 
However, the suitability of classical systemic treatments as continuous 
long-term therapeutic options is questionable and despite the efforts 
to optimize available treatments by various approaches (combination, 
rotation, sequential, intermittent) in some ‘high-need’ patients, dis-
ease control is insufﬁcient In those ‘high-need’ patients, the biologi-
cals may be able to provide a more consistent control of symptoms 
with conserveration of a good safety proﬁle.
So far our information is restricted to clinical trials. However, such 
data do not reﬂect the everyday situation in the dermatologists’ ofﬁce.
In addition, patients categories in trials do not reﬂect the high-need
population for whom those biologicals are indicated for. It is there-
fore of great importance that patients treated with these new agents 
are monitored carefully and systematically to optimize the treatment 
of psoriasis patients with biologicals. As treatment with biologicals is 
restricted to high need patients with many years previous history of 
serious disease, long-term treatment with biologicals is anticipated 
for. Therefore, long-term consistent monitoring and patient databases 
are very important. 
To evaluate the efﬁcacy, safety and adverse events of etanercept and
efalizumab in daily practice, a prospective cohort study was carried 
out between February 2005 and March 2006. The cohort represented 
a high-need population. To obtain data a special consulting-hours was 
set up where psoriasis patients with biological treatment were seen 
on a regular basis and monitored by laboratory results, and special 
forms were made so reported side effects, concomitant medications, 
PASI-scores and adverse events could easily be written down. Results 
were put into a specialized database. These results provide us new 
and important information about safety, adverse events and efﬁcacy
in high-need psoriasis patients in clinical practice and help us to im-
prove management of the treatment of psoriasis patients with these 
agents.
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ORIGINAL ARTICLE
Etanercept and efalizumab treatment for high-need psoriasis. Effects
and side effects in a prospective cohort study in outpatient clinical
practice
MAARTJEA.M. BERENDS, RIEKE J. B. DRIESSEN, ANNECHIENM.G. LANGEWOUTERS,
JAN B. BOEZEMAN, PETER C. M. VAN DE KERKHOF & ELKE M. G. J. DE JONG
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands
Abstract
Background: Since the beginning of 2005, etanercept and efalizumab are officially registered and reimbursed for the
treatment of recalcitrant psoriasis in The Netherlands. Objective: The evaluation of the efficacy, safety and adverse events of
etanercept and efalizumab treatment in daily practice. Methods: A prospective cohort study was carried out for patients
treated with etanercept or efalizumab between February 2005 and March 2006. Results: Over the past 13 months 45
individuals were treated with etanercept and 17 subjects were treated with efalizumab. The cohort represented a high-need
population. At week 12, 82% of the subjects treated with 2650 mg etanercept/week and 71% of the subjects treated with
2625 mg etanercept/week reached a PASI-50. Efficacy of etanercept treatment was comparable to the results of clinical
trials. For efalizumab, efficacy in responding patients was also comparable to clinical trial data, but the percentage of
dropouts was substantial. During biologic treatment, safety was preserved and mainly mild adverse events were reported.
Conclusion: Etanercept and efalizumab are effective and safe treatments of psoriasis, even in a high-need population.
Etanercept was able to sustain the clinical improvement throughout 24 weeks, whereas efalizumab was not in 47% of
subjects.
Key words: Clinical practice, efalizumab, etanercept, high-need psoriasis
Introduction
Etanercept and efalizumab belong to the newest
antipsoriatic therapies, known as biologicals. These
drugs became of particular interest for the treatment
of psoriasis after discovering the high potential
combined with assumed fewer side effects than
regular systemic antipsoriatic therapies.
In September 2004, the European Union
approved etanercept and efalizumab for the treat-
ment of adult patients with moderate-to-severe
plaque psoriasis who failed to respond to, or have a
contraindication to, or are intolerant of other
systemic therapies (1). In The Netherlands, these
pharmaceuticals have been reimbursed by health
insurance since the beginning of 2005. Etanercept
binds specifically to TNF-a and blocks its interac-
tion with cell surface TNF-a receptors (2).
Efalizumab binds to human CD11a, the a-subunit
of leukocyte function antigen-1 (LFA-1), thereby
inhibiting the adhesion of leukocytes to other cell
types (3).
Many well-designed trials have been performed to
study the efficacy of biologicals in considerable
numbers of patients. The use in daily practice,
however, is different from the setting in which trials
are conducted. From February 2005 until March
2006, we started with biologic therapy in 62
individuals with recalcitrant psoriasis in our out-
patient clinic.
In this report we describe the first year of
experience in treating patients in daily clinical
practice with moderate-to-severe plaque psoriasis
with etanercept and efalizumab. Evaluating the
efficacy and safety of biologic agents in clinical
practice rather than in clinical trials provides
relevant additional information about these new
therapeutic strategies in the day-to-day care of
psoriasis.
Correspondence: Maartje Berends, Department of Dermatology, Radboud University Medical Centre, PO Box 9101, 6525 GL Nijmegen, The Netherlands.
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Patients and methods
Patients
Data were collected prospectively, using a standard
form at each visit for all patients treated with
etanercept or efalizumab between February 2005
and March 2006. Patients came into consideration
for one of these treatments if they had failed to
respond to phototherapy, methotrexate and cyclos-
porin in the past, or if they had a contraindication to,
or were intolerant of one of these treatments. At the
same time, patients had to have a minimum psoriasis
area and severity index (PASI) of 10 at the time of
screening, as stated in the guidelines of the Dutch
Society of Dermatology and Venereology.
Charts were reviewed for demographics and
baseline characteristics, including age, sex, existence
of psoriatic arthritis, duration of psoriasis, baseline
PASI, previous dermatological treatments and the
number of concomitant non-dermatological drugs.
Protocol
Before treatment, a chest X-ray and a Mantoux skin
test were performed to exclude tuberculosis. Patients
were treated with etanercept or efalizumab, depend-
ing on the physician’s preference. For etanercept,
two dosing regimens were used randomly, either
50 mg subcutaneously (s.c.) twice weekly for 12
weeks, followed by 25 mg s.c. twice weekly for 12
weeks (dosage schedule 1), or 25 mg s.c. twice
weekly for 24 weeks (dosage schedule 2). After 24
weeks, patients interrupted etanercept treatment for
an indefinite period according to the approved
EMEA label. Efalizumab was given in a single
conditioning dose of 0.7 mg/kg s.c., followed by
1 mg/kg weekly (up to a maximum single dose of
200 mg).
Contraindications for etanercept treatment were
an active infection or increased susceptibility for
infections (including immunocompromised indivi-
duals), a history of tuberculosis, the existence of a
demyelinating disease and pregnancy. Relative con-
traindications were the existence of cardiac decom-
pensation, a blood dyscrasia, a malignancy in recent
history, the presence of an anti-nuclear antibody
(ANA) positive autoimmune disease or chronic
exposition to actinic radiation in the past.
Contraindications for therapy with efalizumab
were the presence of pustular, guttate or erythro-
dermic psoriasis during screening, a previous malig-
nancy (basal cell carcinomas excluded), active
infection or increased susceptibility for infections
(including immunocompromised individuals), active
tuberculosis, and pregnancy. Relative contraindica-
tions were the existence of leukocytosis, lymphocy-
tosis or thrombocytopenia, the presence of an ANA
positive autoimmune disease or chronic exposition
to actinic radiation in the past.
Patients were allowed to use topical dermatologi-
cal therapies during biologic treatment. An effort
was made to confine the use of concomitant systemic
dermatological therapies in cases of unsatisfactory
effectiveness of etanercept or efalizumab. Termin-
ation of other non-dermatological drugs was found
unnecessary.
Visits were scheduled every 4 weeks during the
first 12 weeks, every 6 weeks until week 24 and every
12 weeks thereafter. At each visit, the PASI and
adverse events were documented. Furthermore,
laboratory tests were conducted, including haema-
tological analysis, serum chemistry, urinalysis and
ANA. After 12 weeks of therapy, the treatment
protocol required an improvement in PASI of at
least 50% for both etanercept and efalizumab
patients. Patients who did not meet this criterion
were excluded from therapy according to the
reimbursement guidelines. In some of these cases,
treatment with the other available biologic agent was
started thereafter. The administration of etanercept
or efalizumab was discontinued if patients developed
a serious infection; therapy was restarted after
recovery. Likewise, therapy was interrupted in cases
of elective surgical procedures.
Analysis
Data from charts and forms were transported to a
database and analysed to define treatment efficacy
by means of PASI, with primary efficacy endpoints
including the achievement of an improvement in
PASI relative to a baseline of at least 50% or 75%
(PASI-50 and PASI-75, respectively). Efficacy ana-
lysis of the first 12 weeks of treatment was made
according to the intention-to-treat principle. Missing
PASI at given time points were imputed using the
last observation carried forward (LOCF). Because
there were large differences in the follow-up periods
of subjects, efficacy of the next 12 weeks was
measured by means of a per protocol analysis.
Reported adverse events and abnormal laboratory
values were summarized. If patients received both
etanercept and efalizumab treatment, they were
considered two individual subjects and chart analysis
was performed twice. Multiple occurrences of the
same adverse event in a single subject were counted
once.
Results
Demographics
Over the past 13 months 45 subjects were treated
with etanercept, of whom 28 received a dose of
50 mg s.c. twice weekly for 12 weeks, followed by
25 mg s.c. twice weekly for 12 weeks (dosage
schedule 1) and 17 received a dose of 25 mg s.c.
twice weekly for 24 weeks (dosage schedule 2).
Etanercept and efalizumab treatment for psoriasis 77
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Seventeen subjects were treated with efalizumab.
Overall, 55% were male, the mean age was 50.9
years and the mean duration of psoriasis was 21.6
years. Out of all the subjects, 18 suffered from
psoriatic arthritis. The mean PASI at baseline was
19.8. Patients had previously received four to 10
different dermatological therapies, with an average
of 6.7 treatments per patient. The mean number of
systemic therapies that patients had used before the
start of biologic treatment was 3.3, indicating a high-
need population. Some patients had even used
biologic agents in the past, mostly in the context of
clinical trials. These included etanercept, alefacept,
efalizumab, infliximab and onercept. The mean
number of concomitant non-dermatological drugs
was 2.2 (Table I).
Patients were treated for various periods. The
overall mean duration of treatment was 26 weeks
(interruptions after 24 weeks or for other reasons
excluded), with a range of 5–46 weeks in the
etanercept dosage schedule 1 group, 11–49 weeks
in the etanercept dosage schedule 2 group and 6–32
weeks in the efalizumab-treated group.
Efficacy
Twenty-three subjects (82%) in the etanercept
dosage schedule 1 group, 12 subjects (71%) in the
etanercept dosage schedule 2 group and 10 subjects
(59%) in the efalizumab group achieved a PASI-50
at week 12. At the same time, respectively, 39%,
24% and 6% achieved a PASI-75 (Table II).
For 14 subjects in the etanercept dosage schedule
1 cohort, 14 subjects in the dosage schedule 2 cohort
and four subjects in the efalizumab cohort, PASI at
24 weeks of treatment were available. After per
protocol analysis, data revealed the achievement of a
PASI-50 in respectively 71%, 79% and 100% of
these subjects. Nevertheless, these efficacy percen-
tages are calculated by dividing on the remaining
number of subjects at week 24. In the efalizumab
cohort, the dropout rate due to lack of efficacy at
Table I. Baseline demographic data and disease characteristics.
Etanercept
Efalizumab AllDosage schedule 1 Dosage schedule 2
Age, years
Range 28–71 39–42 27–71 27–71
Mean (¡SEM) 49.6 (1.7) 52.9 (2.3) 51.1 (3.2) 50.9 (1.3)
Gender, no. (%)
Male 16 (57) 9 (53) 9 (53) 34 (55)
Female 12 (43) 8 (47) 8 (47) 28 (45)
Psoriasis, no. (%)
With psoriatic arthritis 11 (39) 2 (12) 5 (29) 18 (29)
Without psoriatic arthritis 17 (61) 15 (88) 12 (71) 44 (71)
Duration of psoriasis (years)
Range 3–42 5–54 3–40 3–54
Mean (¡SEM) 20.7 (1.9) 28.0 (3.1) 16.8 (2.5) 21.6 (1.5)
Baseline PASI score
Mean (¡SEM) 25.1 (2.2) 16.3 (1.2) 14.7 (1.3) 19.8 (1.2)
Previous treatments (no.)
Range, total 4–10 4–9 4–9 4–10
Range, systemic treatments 1–6 2–6 2–5 1–6
Mean, total (¡SEM) 6.8 (0.3) 6.4 (0.3) 6.8 (0.3) 6.7 (0.2)
Mean, systemic treatments (¡SEM) 3.5 (0.2) 3.0 (0.2) 3.4 (0.3) 3.3 (0.1)
Types of previous treatments used, no. of patients (%)
Topical steroids/ vitamin D analogues 28 (100) 17 (100) 17 (100) 62 (100)
Dithranol 19 (68) 12 (71) 14 (82) 45 (73)
Methotrexate 28 (100) 17 (100) 16 (94) 61 (98)
UVB 25 (89) 14 (82) 15 (88) 54 (87)
PUVA 21 (75) 14 (82) 11 (65) 46 (74)
Acitretin 20 (71) 12 (71) 13 (76) 45 (73)
Cyclosporin A 21 (75) 9 (53) 13 (76) 43 (69)
Fumaric acid 15 (54) 6 (35) 7 (41) 28 (45)
Etanercept 2 (7) 3 (18) 3 (18) 8 (13)
Alefacept 2 (7) 2 (12) 4 (24) 8 (13)
Efalizumab 6 (21) 0 (0) 0 (0) 6 (10)
Infliximab 2 (7) 0 (0) 2 (12) 4 (6)
Onercept 1 (4) 2 (12) 0 (0) 3 (5)
Concomitant non-dermatological drugs, no.
Range 0–9 0–6 0–9 0–9
Mean (¡SEM) 2.5 (0.5) 1.7 (0.4) 2.1 (0.6) 2.2 (0.3)
SEM5standard error of the mean. Dosage schedule 1: 50 mg twice weekly for 12 weeks, followed by 25 mg twice weekly. Dosage schedule
2: 25 mg twice weekly.
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week 24 was high, i.e. eight subjects (47%)
(Table III).
For 18 of all the etanercept-treated subjects, a
PASI beyond 24 weeks was available. Analysis of the
effect of treatment interruption, after 24 weeks to
conform to EMEA guidelines or due to other
reasons, on PASI in this group showed that these
patients encountered a mean increase in PASI of
2.97 (SEM¡1.07) during interruption, with a mean
increase of 0.65 per week (Figures 1 and 2).
Currently, 12 of these subjects have reached a
PASI-50 and 8 have achieved a PASI-75. The only
subject in the efalizumab group, who was treated
beyond 24 weeks, has currently achieved an
improvement in PASI relative to baseline of 69.5%.
Despite a considerable reduction in the severity of
disease in many patients, the effects of biologic
therapy were unsatisfactory several times. In these
cases, concomitant use of other antipsoriatic thera-
pies was necessary. In 91% of all etanercept-treated
patients and 82% of all efalizumab-treated patients,
topical corticosteroids or vitamin D analogues were
used in addition to biologic treatment. Other
concomitant therapies included methotrexate,
dithranol, acitretin and fumaric acid. Five subjects
in the etanercept dosage schedule 1 cohort, one
subject in the etanercept dosage schedule 2 cohort
and one patient in the efalizumab cohort used one of
these therapies.
Side effects
In general, etanercept and efalizumab treatment was
well tolerated, and mainly mild adverse events were
reported. The most common side effects reported
(with an overall incidence of more than 20%) were
upper respiratory infections, flu-like symptoms and
gastrointestinal symptoms. No subjects were diag-
nosed with tuberculosis, although, after the marker
study period, we discovered three patients with
possible latent tuberculosis who had to be prophy-
lactically treated with isoniazid. Malignancies were
Table II. Efficacy results after 12 weeks of biologic therapy (intention to treat analysis).
Etanercept
Efalizumab AllDosage schedule 1 Dosage schedule 2
No. of patients ITT 28 17 17 62
No. of dropouts due to lack of efficacy 1 (4) 2 (12) 5 (29) 8 (13)
>50% improvement in PASI, no. (%) 23 (82) 12 (71) 10 (59) 45 (73)
>75% improvement in PASI, no. (%) 11 (39) 4 (24) 1 (6) 16 (26)
v50% improvement in PASI, no. (%) 4 (14) 3 (18) 2 (12) 9 (15)
ITT5intended to treat with biologic therapy; PASI5psoriasis area and severity index. Dosage schedule 1: 50 mg twice weekly for 12 weeks,
followed by 25 mg twice weekly. Dosage schedule 2: 25 mg twice weekly. Percentages are calculated by dividing on the number of subjects
intended to treat.
Table III. Efficacy results after 18 and 24 weeks of biologic therapy (per protocol analysis).
Etanercept
Efalizumab AllDosage schedule 1 Dosage schedule 2
No. of patients at baseline 28 17 17 62
No. of patients with unfinished follow-up
At week 18 10 1 6 17
At week 24 13 0 5 18
No. of dropouts due to lack of efficacy
At week 18 1 2 6 9
At week 24 1 3 8 12
Remaining no. of patients
At week 18 17 14 5 36
At week 24 14 14 4 32
>50% improvement in PASI, no. (%)
At week 18 15 (88) 11 (79) 5 (100) 31 (86)
At week 24 10 (71) 11 (79) 4 (100) 25 (78)
>75% improvement in PASI, no. (%)
At week 18 8 (47) 9 (64) 1 (20) 18 (50)
At week 24 7 (50) 8 (57) 1 (25) 16 (50)
v50% improvement in PASI, no. (%)
At week 18 2 (12) 3 (21) 0 (0) 5 (14)
At week 24 4 (29) 3 (21) 0 (0) 7 (22)
Dosage schedule 1: 50 mg twice weekly for 12 weeks, followed by 25 mg twice weekly. Dosage schedule 2: 25 mg twice weekly. Efficacy
was measured by means of a per protocol analysis. Percentages are calculated by dividing on the remaining number of subjects at week 18
and 24.
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found in two subjects. One 48-year-old man was
diagnosed with an oesophageal carcinoma, as well as
with three squamous cell carcinomas and Bowen’s
disease during etanercept therapy. Another etaner-
cept-treated patient developed a basal cell carcinoma
and a squamous cell carcinoma. Both patients were
treated with phototherapy in the past.
Infections were reported 38 times. These included
upper and lower respiratory infections, skin infec-
tions, eye infections, urinary tract infections and oral
infections. Eye infections were seen four times in the
etanercept group only and none in the efalizumab
group (Table IV).
Etanercept therapy was interrupted 12 times:
seven times because of upper or lower respiratory
infections, twice because of flu-like symptoms and
three times due to an elective surgical procedure.
Efalizumab treatment was only interrupted once,
due to the scheduling of surgery. Five patients
required hospital admission: once because of severe
arthralgia in combination with a high increase in the
C-reactive protein (118 mg/l) value and four times
through severe exacerbation of psoriasis. The latter
were seen after abrupt discontinuation of other
systemic antipsoriatic treatments before the start of
biologic therapy, and consecutively had a poor
response on biologic treatment; after the occurrence
of infection during biologic therapy, that caused
discontinuation of biologic therapy; or both. Four of
the subjects, who needed admission to hospital, were
treated with efalizumab at that time, including the
patient with arthralgia.
Seven efalizumab-treated patients (41%) reported
changes in the morphologic pattern of psoriasis since
Figure 1. Effect of etanercept interruption at week 24 in 18 subjects.
Figure 2. Increase in PASI during treatment interruption in 18 subjects.
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the start of treatment. Such morphologic changes
did not occur in the etanercept cohort.
Routine laboratory monitoring did reveal leuko-
cytosis (white blood cell count w 116109/l) in 23
patients at one or more moments during therapy.
Twelve of these patients were in the etanercept
cohort (27%) and 11 patients were in the efalizumab
group (65%). Fourteen times leukocytosis was
combined with an increased CRP (CRPw10 mg/
l): six times in the etanercept group and eight times
in the efalizumab group. However, only seven
patients reported clinical signs of infection (etaner-
cept: n54, efalizumab: n53), principally diagnosed
as mild upper respiratory infections and skin
infections. Thrombocytopenia was seen three times,
one in every treatment group. No other notable
changes in laboratory markers were found during
therapy.
Current status
At the beginning of March 2006, 48 subjects were
still on biologic treatment, including three subjects
who had temporarily discontinued therapy. Of the
efalizumab cohort, 47% discontinued therapy
because of lack of efficacy. On the contrary, only
six subjects (13%) terminated etanercept treatment.
One of these six subjects (i.e. the patient with the
oesophageal carcinoma and squamous cell carcino-
mas) discontinued therapy because of these adverse
events, diagnosed at week 44.
Discussion
Our aim was to evaluate the efficacy, safety and
adverse events of etanercept and efalizumab treat-
ment in the outpatient clinic. Data were obtained
from a 1-year follow up of 62 patients. The cohort
represented a high- need population, concerning the
treatment of psoriasis.
A total of 82% of the subjects in the etanercept
dosage schedule 1 group and 71% of the subjects in
the etanercept dosage schedule 2 group achieved a
PASI-50 at week 12; 39% and 24%, respectively,
achieved a PASI-75 at this point. These efficacy data
are comparable with the results of several clinical
Table IV. Adverse events.
Etanercept
Efalizumab AllDosage schedule 1 Dosage schedule 2
Infections, no. (%)
Upper respiratory infections 13 (46) 6 (35) 2 (12) 21 (34)
Lower respiratory infections 2 (7) 2 (12) 1 (6) 5 (8)
Skin infections 0 (0) 2 (12) 2 (12) 4 (6)
Eye infectionsa 0 (0) 4 (24) 0 (0) 4 (6)
Urinary tract infections 1 (4) 2 (12) 0 (0) 3 (5)
Oral infections 0 (0) 1 (6) 0 (0) 1 (2)
(Pre)malignancies, no. (%)
Actinic keratosis 1 (4) 1 (6) 1 (6) 3 (5)
Squamous cell carcinoma 2 (7) 0 (0) 0 (0) 2 (3)
Bowen’s disease 1 (4) 0 (0) 0 (0) 1 (2)
Basal cell carcinoma 1 (4) 0 (0) 0 (0) 1 (2)
Esophageal carcinoma 1 (4) 0 (0) 0 (0) 1 (2)
Skin reactions, no. (%)
Skin reactionsb 6 (21) 4 (24) 0 (0) 10 (16)
Pruritus 2 (7) 3 (18) 4 (24) 9 (15)
Injection site reactions 5 (18) 1 (6) 1 (6) 7 (11)
Edema 1 (4) 1 (6) 1 (6) 3 (5)
Hair loss 1 (4) 0 (0) 1 (6) 2 (3)
Miscellaneous, no. (%)
Flu-like symptomsc 5 (18) 4 (24) 6 (35) 15 (24)
Gastrointestinal symptomsd 5 (18) 4 (24) 5 (29) 14 (23)
Arthralgia 3 (11) 6 (35) 2 (12) 11 (18)
Headache 1 (4) 4 (24) 7 (41) 12 (19)
Otalgia 1 (4) 2 (12) 0 (0) 3 (5)
Eye irritation 1 (4) 1 (6) 0 (0) 2 (3)
Hypoglycaemias 0 (0) 1 (6) 0 (0) 1 (2)
Dyspnea 0 (0) 0 (0) 1 (6) 1 (2)
Epistaxis 0 (0) 0 (0) 1 (6) 1 (2)
Hospital admission 0 (0) 1 (6) 4 (24) 5 (8)
Any 23 (82) 17 (100) 14 (82) 54 (87)
Dosage schedule 1: 50 mg twice weekly for 12 weeks, followed by 25 mg twice weekly. Dosage schedule 2: 25 mg twice weekly. Multiple
occurrences of the same event in a single subject were counted once in the overall incidence. aSuch as blepharitis, conjunctivitis; bsuch as
drug eruption, prurigo nodularis, photodermatosis, mollusca contagiosa, mycosis, urticaria, eczema, pseudofolliculitis barbae; csuch as
myalgia, fatigue, chills, sweating; dsuch as nausea, vomiting, diarrhea, abdominal pain, loss of appetite, rectal bleeding.
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trials (4–6). During the next 12 weeks, the efficacy of
etanercept treatment remained stable.
Efalizumab efficacy data were much less satisfy-
ing. A total of 59% of all subjects achieved a PASI-
50, but only 6% achieved a PASI-75 at week 12.
Furthermore, after 24 treatment weeks, eight of the
17 efalizumab-treated patients discontinued therapy
because of lack of efficacy. In addition, four subjects
in this cohort needed hospital admission during
therapy. This is in contrast with efalizumab clinical
trial data, which show significant PASI improve-
ments in large numbers of patients (7–11).
It has to be kept in mind that these data are
presumably influenced by the use of concomitant
antipsoriatic therapies. More than 80% of all
subjects needed concomitant use of topical steroids
or vitamin D analogues, and in seven of all the
subjects, the use of other systemic antipsoriatic
treatments or dithranol was even necessary. It is an
important goal to investigate further the effect of
combining biologicals with other antipsoriatic treat-
ments. Combining etanercept with methotrexate has
already been found to be more effective in the
treatment of rheumatoid arthritis than etanercept
monotherapy (12).
Abrupt cessation of other systemic antipsoriatic
treatments before starting with biologicals could
possibly influence the efficacy of these drugs in a
negative manner. Likewise, interruption of etaner-
cept treatment after 24 weeks, as we did according to
the EMEA label, appears to elicit a substantial fall in
treatment benefits. Taking this into account, we
recommend a gradual tapering of systemic antipsor-
iatic treatments before, or partially overlapping,
biologic therapy. In addition, continuing treatment
after 24 weeks instead of interrupting therapy at that
point would be of benefit to the patient.
Both etanercept and efalizumab were well toler-
ated. Fifty-four patients reported one or more side
effects, but those were mainly mild. The most
frequently reported side effects were upper respira-
tory infections, flu-like symptoms and gastrointest-
inal symptoms. Eye infections were only seen in the
etanercept cohort, as well as eye irritation. Recently,
Taban et al. accomplished a literature review about
inflammatory eye disease associated with etanercept
therapy, and found that ocular inflammation is a
potential adverse event following the use of etaner-
cept (13). Of significance as well are the nine
subjects in the etanercept cohort reporting arthral-
gias. Only two of these subjects suffered from
psoriatic arthritis. Physical examination of the other
subjects by a rheumatologist did not reveal a
significant arthritis.
Changes in the morphologic pattern of psoriasis
since the start of treatment were reported by 41% of
the efalizumab-treated patients. In some cases this
meant the manifestation of psoriasis in regions
that were not affected earlier; in other cases, the
plaque-type psoriasis appeared to change in another
type, such as guttate or pustular psoriasis. This
phenomenon was also seen in other trials, although
an incidence of 3.2% was mentioned (14).
As leukocytosis is often seen during treatment
with efalizumab, it should not be used as an infection
parameter. Therefore, to monitor infections, physi-
cians should pay better attention to the clinical
symptoms of infection, reported by patients.
Furthermore, as latent tuberculosis was found three
times in our cohort, we recommend performing
tuberculosis screening in all patients who are
candidates for biologic therapy.
In conclusion, prospective cohort monitoring of
high-need psoriasis patients on systemic treatments,
especially on biologicals, is worthwhile. Information
about treatment with these new drugs in daily
clinical practice is important for adjusting treatment
schedules and guidelines.
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5.1 General focus
The studies carried out in this thesis were designed to optimize the 
available antipsoriatic treatments with respect to safe disease control. 
The following aims were deﬁned:
1. To understand the improved efﬁcacy of a combination therapy
 of calcipotriol and betamethasone dipropionate in terms of
 effects on T-cell subsets and epidermal proliferation and dif-
 ferentiation. 
2. To deﬁne the degree of Methotrexate-induced hepatotoxicity
 and to develop new strategies for monitoring this hepatotoxicity
3. To set up a special unit and a database for high-need psoriasis
 patients treated with biologicals to provide best possible care
 and to evaluate the efﬁcacy and safety of these relatively new
 treatments in daily practice.
In the discussion we will further integrate the observations in the 
present thesis with available data found in the literature. Further we 
will propose some suggestions for modiﬁcation of the available guide-
lines. Finally we will propose some future directions.
Aim I: To understand the improved efﬁcacy of a combination
therapy in terms of effects on T-cell subsets and epidermal prolif-
eration and differentiation.
Chapter 2 compared the clinical and histological effects of betametha-
sone diproprionate (topical corticosteroid) and calcipotriol (vitamin D3 
derivative) as monotherapy and as combination. It is concluded that 
the action spectra of calcipotriol and betamethasone on the psoriatic 
plaque are different and that the combination has effects on T-cell 
subsets, beyond the addition of the effects of mono therapies with 
major reductions of all studied T-cell subsets in epidermis and dermis 
(CD4, CD8, CD25, CD45RO, CD45RA, CD94, CD161 and CD2). Com-
bination therapy enables a reduction of the required amount of both 
monotherapies thereby reducing the risk of side effects. Reduction of 
side effects in combination with conservation of effect can indeed be 
regarded as optimization of a therapy. 
 Since 2003 the two-compound product, Dovobet®/Daivobet®/
Taclonet®, containing calcipotriol 50 µg/g plus betamethasone di-
propionate 0.5 mg/g is available on the market for the treatment of 
psoriasis. Clinical efﬁcacy has been proved to be signiﬁcantly better
than monotherapy with the above named individual ingredients with 
at least similar or even signiﬁcantly better safety proﬁle for the combi-
nation therapy1-3. Safety data of up to a 52-week treatment period are 
available4. The advised treatment scheme is once daily application for 
4 weeks and then intermittently as needed3. 
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 Topical agents can be combined with each other, with photo-
therapy and systemic treatments. Despite of decades of experience 
with clinical usage of topical agents, evidence-based data for efﬁcacy
and safety are limited. Furthermore, little information is available on 
the combination of topical treatments with systemic agents. The most 
extensive available evidence-based data until now are on the vitamin 
D3 analogue calcipotriol as monotherapy or in combination with an-
other topical or systemic therapy and the above described two-com-
pound combination. 
 To evaluate and optimize the treatment of psoriasis in order 
to maintain clinical efﬁcacy with minimal side effects and to deﬁne
an optimal appropriate therapeutic ladder, well-designed studies with 
topical treatments and combination therapies are required to support 
evidence-based treatment guidelines.
Aim II: To deﬁne the degree of Methotrexate-induced hepatotox-
icity and to develop new strategies for monitoring this hepato-
toxicity.
Chapter 3 is about MTX hepatotoxicity. 
 MTX is a folic acid antagonist and there is substantial evidence 
that it acts by inhibiting DNA synthesis. Possibly, as a consequence it 
possesses potent anti-inﬂammatory effects on T-cell mediated immune
responses as it inhibits proliferation and induces apoptosis in activat-
ed T-cells and blocks the abnormal rapid epidermal cell proliferation, 
both responsible for the characteristic skin lesions in psoriasis5.
 MTX plays a central role in the treatment of severe psoriasis in 
Europe6. This role is strengthened by the fact that reimbursement of 
the expensive biologicals in Europe is restricted to ‘high-need’ psoria-
sis patients. ‘High-need’ psoriasis patients may be deﬁned using crite-
ria that include disease severity and resistance and/or intolerance to 
a number of conventional therapies7, 8, like MTX. Furthermore, in the 
future, MTX will more and more be used in combination with one of 
these biologicals. 
 However, long-term MTX therapy is associated with some seri-
ous adverse reactions as myelosuppression, interstitial pneumonitis 
and hepotoxicity9. However, the reported frequency of MTX-induced 
liver ﬁbrosis and cirrhosis in psoriasis patients varies widely in dif-
ferent studies10-12. High numbers of prevalence of liver ﬁbrosis and
cirrhosis and uncertainty about a delineated effect led to dermatologic 
guidelines that stipulate monitoring periodically after every 1500 mg 
cumulative dose of MTX13. Until now the gold standard in the assess-
ment of histological changes is a liver biopsy14. The need for a liver 
biopsy impedes the prescription of MTX.
 The results of a Dutch survey, conducted among dermatolo-
gists and residents in dermatology, revealed that the need for liver 
biopsies in combination with the frequent check-ups and the lack of 
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consensus between rheumatologists, hepatologists and dermatolo-
gists restrict the adherence to the guideline of the Dutch Society of 
Dermatology and Venereology with respect to the treatment with MTX 
for severe chronic plaque psoriasis. Since MTX retains a central role in 
the treatment of psoriasis in Europe and because of the resemblance 
of the Dutch guideline to the international guidelines13, our results 
may, at least to some extent, be applicable to other countries.
 The obtained knowledge that the liver biopsy is one of the 
reasons which impede the prescription of MTX in psoriasis patients 
by dermatologists combined with the great variation in prevalence of 
MTX-induced liver injury in psoriasis suggested that reconsideration 
of our current monitoring strategies for patients on MTX might be war-
ranted. 
 Therefore, in a following study the prevalence and development 
of liver injury in MTX treated psoriasis was evaluated. From this study 
it could be concluded that MTX-related liver injury is less frequent 
than previously thought and mostly occurs at a cumulative dose of
< 6000 mg, running a benign course. Diabetes and overweight are 
signiﬁcantly correlated with liver injury. These results are conﬁrmed
by a recent study15.  These results suggest that monitoring for MTX-
induced liver ﬁbrosis in psoriasis patients with risk factors, as diabe-
tes and overweight should be continued according to the guidelines. 
However, for patients without these risk factors, the guideline might 
be reconsidered.
 The reason that the application of a liver biopsy, amongst other 
things, restricts the adherence to the guideline is that it is compli-
cated by some important limitations. These limitations include the 
risk for complications caused by the procedure: such as pain and lo-
calized bleeding which are more frequent issues and pneumothorax, 
haemothorax, bile peritonitis, haemobilia, and inadvertent puncture 
of the kidney or intestine which occur less often16, 17. The complica-
tion risk of a liver biopsy is approximately 1-2%, with a 0.01-0.1% 
risk of mortality18. Other limitations of a liver biopsy are the sampling 
error, which according to some studies can approach 30%, intra- and 
inter-pathologist inconsistency and discontinuous and semi-quantita-
tive histological scoring systems13, 14, 16, 19-23. Finally, a liver biopsy is an 
expensive procedure, requiring hospitalization. 
 Therefore there is a pressing need for non-invasive, reliable 
alternative methods to monitor MTX-induced liver injury in psoria-
sis patients. It has been shown that liver ﬁbrosis can develop despite
normal serum liver values and normal ultrasound and radioisotope 
scans24. A promising method for monitoring liver damage might be 
the aminoterminal propeptide of procollagen type III (PIIINP). Studies 
have shown that liver biopsies can be avoided when serial PIIINP (once 
per 3 months) are continuously normal18, 25-27. Furthermore, in Hepa-
titis C patients two other, non-invasive methods, the Fibroscan® and 
Fibrotest, have been tested and found promising in monitoring liver 
damage21, 23, 28-32. 
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We performed a pilot study to evaluate the accuracy and feasibility of 
the Fibroscan® and Fibrotest to assess MTX-induced hepatic ﬁbrosis
in psoriasis patients. The promising results suggest that a combina-
tion of Fibroscan® and Fibrotest should prospectively be evaluated 
in monitoring and detecting signiﬁcant MTX-induced liver ﬁbrosis in
psoriasis patients. Also more prospective studies with serial PIIINP 
and liver biopsies as reference should be performed.
 As described above, another limitation of a liver biopsy is its 
shortage of a good histological scoring system. MTX-associated liv-
er injury in a liver biopsy is graded by pathologists according to the 
Roenigk classiﬁcation. However, the Roenigk classiﬁcation is subjec-
tive and insensitive to small changes, particularly when assessing ﬁ-
brosis lumping all biopsies with more than minimal ﬁbrosis as ad-
vanced ﬁbrosis33-35. Furthermore, this classiﬁcation has never been
validated and no literature is known about the inter-observer reliabil-
ity. Since the assessment of liver damage is essential in the manage-
ment of psoriasis patients the results of the Roenigk scoring system 
should be reproducible with little inter-observer error. 
 Our study showed that the interobserver variability of the 
Roenigk score as classiﬁcation system of liver damage is low. Also,
there was a good agreement on biopsies that resulted in a Roenigk 
grade that necessitated change of clinical management (biopsies with 
Roenigk 3a, 3b or 4). 
 A recent study demonstrated preliminary evidence that spe-
ciﬁc polymorphisms of enzymes involved in folate, pyrimidine and pu-
rine metabolism could be useful in predicting clinical response, as in 
efﬁcacy and toxicity, to methotrexate in psoriasis patients36.
 Taken all these aspects into account the use of MTX in the 
treatment of psoriasis patients has been optimized. It has become 
clear that in case of risk factors frequently monitoring for MTX-in-
duced liver damage is indicated. In patients without risk factors, mon-
itoring frequency might be reduced and adapting the guidelines at this 
point is advised. For the present, monitoring should still be done by 
liver biopsy, with Roenigk scoring system having a good inter-observer 
reliability. However, monitoring liver damage in patients without risk 
factors might be done by a combination of non-invasive alternatives of 
the liver biopsy in the future. 
Aim III: To set up a special unit and a database for high-need pso-
riasis patients treated with biologicals to provide best possible 
care and to evaluate the efﬁcacy and safety of these relatively
new treatments in daily practice.
Chapter 4 is about the management, safety and efﬁcacy of the treat-
ment of patients with moderate to severe psoriasis with etanercept 
and efalizumab. 
 Most data about these agents have been retrieved from clini-
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cal trials and only limited long-term data are available. It is therefore 
of great importance that patients treated with these new agents are 
monitored carefully and systematically to optimize the treatment of 
psoriasis patients with biologicals. 
 To evaluate the efﬁcacy, safety and adverse events of etaner-
cept and efalizumab in daily practice, a prospective cohort study was 
carried out between February 2005 and March 2006. The cohort rep-
resented a high-need population. To obtain data a special consulting-
hours was set up where psoriasis patients with biological treatment 
were seen on a regular basis and monitored by laboratory results, 
and special forms were made so reported side effects, concomitant 
medications, PASI-scores and adverse events could easily be recorded. 
Results were transported to a database and analysed. 
 From the results it could be concluded that both etanercept 
and efalizumab are effective and safe treatments for psoriasis, even 
in a high-need population considering duration of one year. Neverthe-
less, frequently monitoring remains required.
 The etanercept efﬁcacy data of our study are comparable with
the results of other clinical trials with 82% and 39% of the patients 
treated with 50mg twice weekly and 71% and 24% of the patients 
treated with 25mg twice weekly reaching a PASI-50 and PASI-75 
respectively8, 37-40. It should be kept in mind however, that these data 
might have been inﬂuenced by the use of concomitant antipsoriatic
therapies. More than 80% of patients used concomitant topical ster-
oids or vitamin D analogues, 7 patients used concomitant systemic 
antipsoriatic treatments or dithranol.
 However, efalizumab efﬁcacy data were much less satisfying
compared to literature data with only 6% of the patients reaching a 
PASI-75 at week 128, 37, 39, 39, 40. These results might be explained by 
the fact that efalizumab was sometimes started in patients with an 
unstable form of psoriasis, for example after abrupt cessation of other 
systemic antipsoriatic therapies (MTX or cyclosporine).
 Clinical trials have shown, as described in the introduction, 
that PASI response rates continue to improve after week 1237. Our 
results agree with those data. Furthermore, interruption of etanercept 
treatment after 24 weeks, as we did according to the EMEA label, ap-
pears to elicit a substantial fall in treatment beneﬁts.
 In daily practice, patient category indicated for biological treat-
ment appears to be a real ‘high-need’ one with many comorbidities, 
comedication and an extended history of previous used antipsoriatic 
systemic treatments. This difference in patient category between daily 
practise and clinical trials and limited available long-term data require 
a strict prospective cohort monitoring. 
 All the results obtained by our study can lead to an optimiza-
tion of the use of biologicals in the treatment of patients with psoria-
sis. These steps are put into recommendations for adaptation of the 
guideline and future directions to further optimize their usage.
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5.2 Recommendations for adaptation of available  
 guidelines
Based on guidelines of the NHG and the Dutch Society of Dermatol-
ogy and Venereology41-43 but also based on the information available in 
international reviews (Bologna) it is evident that a ‘stepwise approach’ 
should, whenever possible, start with topical therapy. 
  
Calcipotriol/betamethasone dipropionate
According to the NHG standard Psoriasis medical treatment should 
be started with a class III topical corticosteroid once a day for 4 weeks 
(with a maximum of 100 grams a week), or with calcipotriol twice a 
day for 8 weeks (with a maximum of 100 grams week). In case this has 
insufﬁcient effect, combination therapy with calcipotriol application
in the morning and a class III topical corticosteroid in the evening is 
advised. Application of a class IV corticosteroid, once a day for 4 weeks 
is the next advised step. Dithranol is advised as ﬁnal step in case none
of the above described treatments are effective enough.
 Based on our own experience in combination with efﬁcacy and
safety data of other studies we propose combination therapy with the 
two compound product Daivobet®, once a day for 4 weeks as ﬁrst step
in the topical treatment of psoriasis patients. 
After those 4 weeks there are a few possible options for management 
of follow-up treatment:
1. Intervention therapy: restarting Daivobet® therapy in case of a
 relapse.
2. Intermittent therapy: application of Daivobet® 3 times a week
 and the rest of the week application of calcipotriol monotherapy.
3. Maintenance therapy: application of calcipotriol monotherapy
 alone.
4. In case of frequent relapses: Daivobet® application as requested
 for a long-term period of time. 
Methotrexate
In case of psoriasis patients with diabetes and/or overweight treated 
with MTX, frequent monitoring for liver damage should be done be-
tween 1500 mg and 6000 mg cumulative MTX dose according to the 
guideline.
 In the absence of risk factors, we propose less frequent moni-
toring. Furthermore, in patients without risk factors we would propose 
monitoring primary by non-invasive alternatives like PIIINP followed 
by a liver biopsy in case of abnormal values.
Biologicals
In case of the biologicals we propose adjusting the guideline at the fol-
lowing points:
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Since PASI response rates have shown to continue to improve after 
week 12 we suggest an evaluation point of efﬁcacy of biologicals after
6 months instead of week 12. 
 We propose continuing treatment of etanercept after 24 weeks 
under strict monitoring instead of interrupting therapy. Furthermore 
we recommend gradual tapering of systemic antipsoriatic treatments 
before, or partially overlapping, biological therapy to prevent unstable 
situations before starting with a biological. Finally we propose less 
strict criteria for prescribing biological treatment for psoriasis pa-
tients. Expected number of requests for biological treatment in 2006 
in the Netherlands was in the order of 1200. However, only 933 re-
quests were received, which is a relatively small quota compared to 
the number of rheumatology requests received. This suggests that our 
criteria are too strict, leading to a relatively young ‘high-need’ popula-
tion, with already extensive history of dermatological treatments with 
secondary exposure to toxic amounts of drugs. 
The following proposals are possible:
1. Patients are directly eligible for treatment with a biological
 without any required previous treatments. 
2. Patients are eligible for treatment with a biological when they
 have been treated with at least one of the classical systemic
 treatments.
3. Patients are eligible when they have been treated with at least
 2 of the classical systemic therapies.
Since the restricted experience with biologicals in the dermatology and 
limited available long-term data we propose gradual adaptation of the 
guideline and liberalize criteria by requiring at least 2 instead of 3 
classical systemic therapies before starting treatment with a biologi-
cal. In rheumatology criteria are already less strict. For example, in 
case of psoriatic arthritis only a moderate-severe arthritis in combina-
tion with previous treatment with MTX is required. 
5.3 Future directions
To further evaluate and optimize the treatment of psoriasis in order 
to maintain clinical efﬁcacy with minimal side effects and to deﬁne an
optimal and appropriate therapeutic ladder, well-designed long-term 
comparative studies with topical treatments and combination thera-
pies are required to support evidence-based treatment guidelines.
 Furthermore, well-designed prospective studies are required to 
continue the search for non-invasive alternatives to monitor MTX-in-
duced liver injury. Besides a prospective study, combining Fibrotest 
and Fibroscan®, a study with amino terminal peptide of type III procol-
lagen (PIIINP) as non-invasive method to detect liver ﬁbrosis and/or
cirrhosis would be interesting. PIIINP was studied before and it has 
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been shown that, when measured levels at regular intervals are con-
sistently normal, liver biopsies can be avoided. Studies about the pa-
tients with high PIIINP but normal liver histology are needed to further 
diminish the number of unnecessary liver biopsies. In addition, a cost-
effective analysis comparing costs and effectivity of a liver biopsy and 
non-invasive alternatives is indicated.
 With respect to the use of biologicals for high-need patients in 
clinical practice it is of importance to continue prospective intensive 
monitoring for efﬁcacy and safety data. Therefore the use of a well-
designed database is of great help and further modifying this database 
is of great importance.
 Since it has been shown that also the biological agents can not 
afford some patients a continuous control of their symptoms, it is an 
important goal to further investigate the efﬁcacy and safety of combi-
nation of biologicals with other antipsoriatic treatments. Combining 
etanercept with MTX has already been found to be more effective in the 
treatment of rheumatoid arthritis than etanercept monotherapy44.
Optimization of the treatment of psoriasis requires developments in 
topical, classical systemic and biological treatments to provide a spec-
trum of options to the individual patient.
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6.1 Summary
Psoriasis is a chronic and incurable disease which challenges many 
patients to manage their disease for decades. A stepwise approach in 
the treatment of psoriasis is advised by guidelines and international re-
views, starting with (1) topical therapy, followed by photo(chemo)therapy 
and classical systemic therapies (2), followed by biologicals (3). 
 In this present thesis we aimed to optimize the treatment of 
psoriasis, reconciling this treatment paradigm and to carry out a study 
in each of these 3 phases of intervention. The three major aims of this 
thesis were:
I To understand the improved efﬁcacy of a combination therapy
 of calcipotriol and betamethasone dipropionate in terms of ef-
 fects on T-cell subsets and epidermal proliferation and differ-
 entiation. (Chapter 2)
II To deﬁne the degree of Methotrexate-induced hepatoxicity and
 to develop new strategies for monitoring this hepatotoxicity.
 (Chapter 3)
III To set up a special unit and a database for high-need psoriasis
 patients treated with biologicals to provide best possible care
 and to evaluate the efﬁcacy and safety of these relatively new
 treatments in daily practice. (Chapter 4)
In chapter 1, at ﬁrst the focus of this thesis is presented, followed
by an overview of the epidemiology, clinical presentation, aetiology, 
pathogenesis, the available treatments of psoriasis and the limitations 
of these treatments. Subsequently the aims of these thesis are formu-
lated.
  
In chapter 2, we compared the effect of the combination of the vita-
min D3 analogue calcipotriol and the corticosteroid betamethasone di-
propianate and of both monotherapies on psoriasis relevant T cells, in 
order to understand the rationale of this successful combination. We 
concluded that the action spectra of calcipotriol and betamethasone 
on the psoriatic plaque are different and that the combination has 
effects on T-cell subsets, beyond the addition of the effects of mono-
therapies.
 
In chapter 3 the degree of methotrexate-induced hepatoxicity and new 
strategies for monitoring this hepatotoxicity were studied.
Results from a Dutch survey showed that, amongst others, the need 
for biopsies restrict the adherence to the guideline. Methotrexate-in-
duced liver injury in our studied population appears to be less frequent 
than previously thought and mostly occurs between 1500-6000 mg
cumulative dose, nevertheless suggesting a continued need for moni-
toring liver injury. Other conclusions were that diabetes mellitus and 
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overweight are risk factors for developing liver damage and that liver 
enzymes do not correlate with histological ﬁndings. From a pilot-study
we concluded that the two used non-invasive methods seem to be of 
beneﬁt in the screening of methotrexate-induced liver damage in pso-
riasis patients. Finally we concluded that the Roenigk classiﬁcation in
the assessment of liver ﬁbrosis is a reliable scoring system.
In chapter 4 we described one year experience with high-need psoria-
sis patients treated with two relatively new treatments, etanercept and 
efalizumab in daily practice and we evaluated their efﬁcacy and safety
in these patients during this year. Data were obtained by setting up 
a special unit and a database. From the results it could be concluded 
that both etanercept and efalizumab are effective and safe treatments 
for psoriasis, even in a high-need population considering duration of 
one year.
In chapter 5 the observations in chapters 2-4 are integrated and posi-
tioned in the context of recent literature. Moreover, recommendations 
for adaptations of the existing guidelines are presented and perspec-
tives for future development are provided.
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6.2 Samenvatting
Psoriasis is een chronische en ongeneeslijke ziekte en vele patiënten 
zijn genoodzaakt om tientallen jaren met hun ziekte te moeten leven. 
De richtlijnen en internationale literatuur adviseren daarom ook een 
stapsgewijze benadering in de behandeling van psoriasis en, voor 
zover mogelijk, te beginnen met (1) topicale therapie, gevolgd, indien 
noodzakelijk, door (2) foto(chemo)therapy en de klassieke systemische 
behandelinen en uiteindelijk gevolgd door de biologicals (3).
 Het doel van dit proefschrift was de behandeling van psoriasis 
te optimaliseren, rekening houdend met bovenstaand behandeling-
sparadigma. Hiertoe zijn in elk van de 3 behandelingsfasen, studies 
verricht. De 3 belangrijkste doelen van dit proefschrift waren:
I Inzicht krijgen in de verbeterde effectiviteit van een combinatie
 therapie van calcipotriol en betamethason dipropionaat in ter-
 men van de effecten op T-cell subsets en epidermale prolifera-
 tie en differentiatie. (Hoofdstuk 2)
II Deﬁniëren van de ernst van methotrexaat geinduceerde lever-
 ﬁbrose en het ontwikkelen van alternatieven om het onstaan
 en de otnwikkeling van deze leverschade aan te kunnen tonen.
 (Hoofdstuk 3)
III Het opzetten van een speciaal spreekuur en een database voor
 ‘high-need’ psoriasis patiënten die behandeld worden met bio-
 logicals om op die manier de best verkrijgbare zorg te kunnen
 leveren en de effectiviteit en veiligheid van deze, relatief nieuwe,
 middelen te kunnen evalueren in de dagelijkse praktijk.
 (Hoofdstuk 4)
In hoofdstuk 1 wordt om te beginnen de focus van dit proefschrift 
gepresenteerd. Hierna volgt een overzicht van de epidemiologie, de kli-
nische presentatie, aetiologie, pathogenese, beschikbare behandelin-
gen en beperkingen van deze behandelingen voor psoriasis. Tot slot 
worden de doelstellingen geformuleerd.
  
In hoofdstuk 2 vergeleken we het effect van de combinatietherapie 
calcipotriol (vitamin D3 analoog) en betamethason dipropionaat en 
van beide monotherapieen op de, voor psoriasis, relevante T cellen 
om op die manier de rationale achter deze succesvolle combinatie te 
ontdekken. We concludeerden dat de werking van calcipotriol en beta-
methasondipropionaat op de psoriasis plaque, van elkaar verschillen 
en dat de combinatie een groter effect heeft op de relevante T-cel sub-
sets dan de monotherapieen afzonderlijk.
 
In hoofdstuk 3 werd de ernst van Methotrexaat geinduceerde leverﬁ-
brose en nieuwe mogelijke strategieen om deze lever schade te moni-
toren bestudeerd. 
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Resultaten van een nederlandse enquete lieten zien dat de noodzaak 
tot het verrichten van een leverbiopt één van de redenen is voor een 
beperkte adherentie van dermatologen aan de richtlijn “Methotrex-
aat” van de nederlandse vereniging voor dermatologie en venereolo-
gie. Methotrexaat geïnduceerde leverschade bleek in onze populatie 
minder vaak voor te komen dan in de literatuur en onstaat met name 
tussen 1500 en 6000 mg cumulatieve dosis Methotrexaat wat duidt op 
de noodzaak voor de controle op het onstaan en de ontwikkeling van 
deze leverschade. Verder concludeerden we dat diabetes mellitus en 
overgewicht risicofactoren zijn voor het ontwikkelen van leverschade 
en dat leverenzymen niet correleren met histologische bevindingen. 
De resultaten van een ‘pilot’-studie deed ons concluderen dat de twee 
gebruikte non-invasieve methodes nuttig lijken te zijn bij de screening 
voor de aanwezigheid van Methotrexaat geïnduceerde signﬁcante lever
ﬁbrose in psoriasis patiënten. Tot slot konden we concluderen dat de
Roenigk classiﬁcatie een betrouwbare score is in de bepaling van aan-
wezigheid van leverﬁbrose.
In hoofdstuk 4 beschreven we ervaringen van de behandeling van 
‘high-need’ patiënten met twee relatief nieuwe middelen, etanercept 
en efalizumab, in de dagelijkse praktijk. Tevens evalueerden de effec-
tiviteit en veiligheid van deze middelen bij deze patiënten gedurende 
dat jaar. Om de data te verkrijgen en te analyseren werden er een 
speciaal ‘biologicals’ spreekuur en een speciale database opgezet. Uit 
de resultaten kon geconcludeerd worden dat gedurende dat jaar, zowel 
etanercept als efalizumab effectieve en veilige behandelingen bleken, 
zelfs in een ‘high-need’ populatie. 
In hoofdstuk 5, de algemene discussie, worden de resultaten van alle 
onderzoeken geplaatst in de context van de recente literatuur. Verder 
worden aanbevelingen gedaan voor het aanpassen van de bestaande 
richtlijnen en worden suggesties gedaan voor verder onderzoek.
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